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Abstract: Polypharmacy increasingly has become a topic of public health concern,
particularly as the U.S. population ages. Drug labels often contain insufficient information
to enable the clinician to safely use multiple drugs. Because many of the drugs are
bio-transformed by cytochrome P450 (CYP) enzymes, inhibition of CYP activity has long
been associated with potentially adverse health effects. In an attempt to reduce the
uncertainty pertaining to CYP-mediated drug-drug/chemical interactions, an interagency
collaborative group developed a consensus approach to prioritizing information concerning
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CYP inhibition. The consensus involved computational molecular docking, spectral
data-activity relationship (SDAR), and structure-activity relationship (SAR) models that
addressed the clinical potency of CYP inhibition. The models were built upon chemicals
that were categorized as either potent or weak inhibitors of the CYP3A4 isozyme.
The categorization was carried out using information from clinical trials because currently
available in vitro high-throughput screening data were not fully representative of the
in vivo potency of inhibition. During categorization it was found that compounds, which
break the Lipinski rule of five by molecular weight, were about twice more likely to be
inhibitors of CYP3A4 compared to those, which obey the rule. Similarly, among inhibitors
that break the rule, potent inhibitors were 2–3 times more frequent. The molecular docking
classification relied on logistic regression, by which the docking scores from different
docking algorithms, CYP3A4 three-dimensional structures, and binding sites on them were
combined in a unified probabilistic model. The SDAR models employed a multiple linear
regression approach applied to binned 1D 13C-NMR and 1D 15N-NMR spectral descriptors.
Structure-based and physical-chemical descriptors were used as the basis for developing
SAR models by the decision forest method. Thirty-three potent inhibitors and 88 weak
inhibitors of CYP3A4 were used to train the models. Using these models, a synthetic
majority rules consensus classifier was implemented, while the confidence of estimation
was assigned following the percent agreement strategy. The classifier was applied to a
testing set of 120 inhibitors not included in the development of the models. Five
compounds of the test set, including known strong inhibitors dalfopristin and tioconazole,
were classified as probable potent inhibitors of CYP3A4. Other known strong inhibitors,
such as lopinavir, oltipraz, quercetin, raloxifene, and troglitazone, were among 18
compounds classified as plausible potent inhibitors of CYP3A4. The consensus estimation
of inhibition potency is expected to aid in the nomination of pharmaceuticals, dietary
supplements, environmental pollutants, and occupational and other chemicals for in-depth
evaluation of the CYP3A4 inhibitory activity. It may serve also as an estimate of chemical
interactions via CYP3A4 metabolic pharmacokinetic pathways occurring through
polypharmacy and nutritional and environmental exposures to chemical mixtures.
Keywords: structure-activity relationship; SAR; QSAR; SDAR; docking; molecular
modeling; inhibitor; CYP3A4; drug-drug interaction; drug-chemical interaction; DDI; DDCI

1. Introduction
Life is an open biological system of co-interacting chemicals, i.e., it is a mixture of chemicals that is
continuously exposed to ambient chemicals through respiratory, ingestive, and transdermal intake.
Although toxicological or pharmacological effects are commonly associated with a single chemical,
exposure to a single chemical entity does not take place. Instead, people are exposed to a mixture of
drugs, nutrients, and environmental pollutants simultaneously. The magnitude of systemic health
effects caused by exposure to a chemical mixture could be additive if the components of the mixture
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act independently or non-additive if appreciable interactions between at least some of the components
take place [1]. When chemical interactions take place, the estimation of joint response from the known
responses to individual components of the mixture and their interactions becomes a problem of
combinatorial complexity. Dosage of individual components (“dose makes the poison”), duration of
exposure, and the intrinsic strength of interactions between the chemicals are some of the factors
determining the overall clinical manifestation. Often at low doses, when biochemical pathways are far
from saturation, the interactions are additive. Additivity is typical of long-term systemic exposures to
environmental pollutants at hazardous waste sites [1,2]. However, the magnitude of the response to an
otherwise low-hazard dose or exposure may change dramatically if the dosage of even one component
in an exposure mixture is significantly increased (e.g., a medication is administered) [3].
Exacerbated effects of drug/environment interactions are encountered in the rapidly growing
subpopulation of elderly because: (1) body functions steadily diminish and physiological sensitivity
increases as aging progresses; (2) pre-existing chronic conditions are common and multiple, and they
are being treated by chronic administration of multiple drugs; and (3) contaminants that are lipophilic
or stored in bone tissue are being released as bone density and the overall fat slowly dissipate with the
increasing age of seniors [4]. The released contaminants may result from: (1) past exposures, including
occupational; and (2) exposures to persistent pollutants that are now banned, such as lead in gasoline,
dichloro-diphenyl-trichloroethane (DDT), polychlorinated biphenyls (PCBs), and polychlorinated
dibenzo-dioxins (PCDDs) [5,6].
Due to polypharmacy, drug-drug/chemical interactions (DDCIs) may be responsible for many
detrimental health effects, yet at present their unequivocal characterization is difficult during the
preclinical evaluation stage of drug development. Because many drugs are metabolized by cytochrome
P450 (CYP) enzymes, other concurrently administered drugs, nutrients, and environmental pollutants
that bind to these enzymes may alter blood and tissue concentration of the drug and, therefore, increase
the potential for adverse health effects [7–13]; this circumstance is especially important for drugs with
narrow therapeutic indices. Such DDCIs can either increase or decrease the metabolic activity of a
CYP enzyme, much like genetic polymorphisms alter patient’s enzymatic activity.
As a part of the microsomal mixed-function oxidase (MFO) enzyme system, CYP enzymes
comprise a large group of multifunctional heme-thiolate monooxygenases involved in phase I
metabolism. The activity of CYP enzymes is regulated at multiple levels. First, there are multiple
binding sites on some, if not all, CYPs [14]. Effector molecules bound to these sites may activate or inhibit
the catalysis. Competitive, non-competitive, and mixed inhibition of CYP enzymes can occur [15,16].
Next, the CYP catalytic cycle requires a transfer of two electrons that are delivered by the NADPH
regeneration system. Components of this system include NADPH-CYP reductase as a primary
component, and at least cytochrome b5 and NADH-cytochrome b5 reductase [17]. Altering the electron
transfer or oxygenation may also affect the CYP activity. The macroscopic rate of catalysis depends on
enzyme concentration. Therefore, CYP inducers, blockers, and dependent nuclear factors play an
important role in CYP metabolism. The concentration of substrate available for oxidation often
depends on the active transport of substrate to endoplasmic reticulum. Induction and inhibition of
transporters is another mechanism that controls DDCIs [18]. In addition, other pharmacokinetic
factors, dosage, partial overlap of CYP phenotypes, sequential metabolism, and unaccountable or
unknown factors may affect the apparent in vivo drug inhibition and DDCIs.
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The complex picture of apparent (e.g., clinical) CYP inhibition represents a challenge for
unambiguous in vitro-to-in vivo extrapolation [19,20]. Recommendations for “dosing and labeling,”
formulated by the U.S. Food and Drug Administration (FDA) in vetted [21] and draft [18] documents,
describe distinctions between the clinical pharmacokinetic- (in vivo) and in vitro-derived information.
The pharmacokinetic picture of DDCIs is more complex. Many DDCIs are transient and context
dependent, so they only apply under specific time frames, doses, or other environmental or genetic
conditions. This information may or may not be on a drug label, especially when the drug is first
released on the market and full understanding of its therapeutic mode of action and contraindications is
still emerging. Often, it takes years after the drug is released on the market to find out the optimal
dosage, contra-indications, or both—a process that may involve multiple passes between the clinic,
FDA, and industry, conjugated to iterative revisions of the drug label, before an optimal and safe
regimen of drug administration is established [22]. Because DDCIs are dose and time dependent,
a DDCI may occur when the putatively interacting substances are administered around the same time,
but not when they are administered several hours apart. Similar considerations would apply to the
route of administration; recently it was pointed out that “contraindications with intravenous midazolam
are inconsistent” [23]. However, “oral midazolam has the most potential for serious reactions. Because
of the high first-pass metabolism with oral midazolam, higher doses are often used. When first-pass
metabolism is inhibited, the amount of drug reaching the system is much higher” [23]. To help with
the initial assessment of putative DDCIs in which new drugs may be involved, the FDA documents
also formulate guidance to using in vitro data for the purpose of drug labeling [21] (also, see the
Experimental Section). We are unaware of statistics about drug labels on which the in vitro
information is present, but it is known that some DDCIs observed in vitro are not clinically significant,
while others observed in vivo are not captured by in vitro methods [24]. The scientific literature rises a
concern that DDCI warnings on some drug labels may be ineffective [22,23,25–28]. Van der Sijs et al. [28]
have suggested that European drug labels may contain “false positive” alerts (from the clinician point
of view, also known as clinician’s “alert fatigue” [29]) and that “these alerts should be further
evaluated for possible improvements in specificity, information content or handling efficiency” [28].
According to a meta-analysis study from the same author, clinicians override up to 96% of drug safety
alerts [25–27]. To tackle the problem, some health care providers develop their own electronic clinical
decision support systems (incorporated in the computerized provider order entry systems as a part of
electronic medical record systems), while others use DDCI information formulated by proprietary
third-party vendors [30–32]. To reduce the effect of false-positive alerts on in silico modeling, the
present work relied on inhibition potency knowledge from similar clinically relevant sources [32,33].
A reliable clinically-relevant in silico DDCI system of alerts has the potential to become an effective
risk-management alternative compared with in vitro testing.
Extrapolation from preclinical results is intricate. Currently, high-throughput screening (HTS) is
often used in drug development. The HTS data are usually collected from in vitro microsomal
bioassays in which: (1) an ersatz MFO system is reconstructed from recombinant components [34];
(2) a chemical derivative of luminescent beetle luciferin (which is converted by CYP to luciferin) is
used as a substrate; and (3) libraries of drugs and drug-like compounds, perhaps, synthesized in the
process of drug discovery, are tested for activity of CYP inhibition, activation or both. In an HTS
experiment, the rate of substrate conversion to products may either increase (activation) or decrease
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(inhibition), or either remain unaffected or mutually contradictory at multiple concentrations of the
tested compound (inconclusive). The activity is usually expressed by a concentration of the tested
compound, which changes the rate of reaction at a specified concentration of substrate by 50%. This is
an inhibition constant of 50% (IC50) if the activity is decreased. By theory (see the Experimental
Section), IC50 itself is inappropriate for in vivo inference; however, it can be related to in vivo health
effects under certain assumptions if the physiological concentration of the inhibitor (drug or other
chemical) in microsomes of the liver is known. Unfortunately, the latter is difficult to appropriately
determine prior to clinical trials.
The first and potentially most severe DDCIs observed in the clinic are expected to be caused by
strong binders to phase I enzymes involved in drug metabolism. Potentially, any chemical that is
metabolized by, or inhibits, CYP P450 enzymes can competitively inhibit the same enzyme
metabolism of other drugs or chemicals. CYP3A4 is the most abundant CYP P450 isoform in the
human liver, constituting 30–40% of the total amount of spectroscopically detectable CYP P450
enzymes [35,36]; the amount of hepatic CYP3A4 can be even further increased by induction as much
as 60% [37]. It is also the dominant CYP isoform in the small intestine, comprising more than 80%
on the enteric-CYP pie chart [36]. It biotransforms endobiotics such as steroids, fatty acids,
prostaglandins, lipid-soluble vitamins, and many structurally diverse xenobiotics, including drugs,
carcinogens, and environmental pollutants [38]. Overall, it is responsible for the metabolism of nearly
50% of known drugs on the market [39]. Among steroids, hepatic CYP3A4 catabolizes testosterone,
progesterone [40], and, together with CYP1A2, as much as 80% of estradiol [41,42]. In this way,
CYP3A4 contributes to regulation of endocrine homeostasis. Changes in the levels of reproductive
hormones and their metabolites are associated with a gamut of physiologic and adverse health effects [43],
ranging from changes in physical appearance to cancers [41–46]. Inhibition and transcriptional
modulation of CYP3A4 activity by drugs and environmental pollutants (such as DDT, PCBs, and
PCDDs) may inadvertently affect these processes by changing the levels of steroid hormones and their
metabolites [47,48]. The effects of interference of drugs and environmental pollutants with steroid
metabolism may be more significant among special populations. For instance, the activity of CYP3A4
is greater among the residents of Danish Faroe Islands who are dietary exposed to high levels of PCBs
and other persistent organohalogen pollutants through traditional consumption of pilot whale blubber [5].
Consistent with its importance, extensive modeling efforts have been made to identify compounds that
inhibit the CYP3A4 activity [33,49–51]. Efforts have been made to estimate the IC50 of in vitro
inhibition of CYP3A4 by chemical compounds using quantitative structure-activity relationship (QSAR)
modeling [51,52]. However, we are unaware of attempts to model the in vivo strength of inhibition.
Kinetic and crystallographic studies reveal unusually wide substrate adaptability of CYP3A4, which
makes it susceptible to inhibition by a wide variety of chemical groups, and, consequently, difficult to
model chemical interactions. Chemicals can act as inducers, effectors, substrates, or inhibitors of
CYP3A4 [53], which makes accurate modeling even more challenging. Therefore, using information
from clinical trials, we developed multiple in silico models of chemical binding and inhibition of the
CYP3A4 isozyme, which can be used to estimate in vivo DDCIs.
Each method targets different features of the chemicals or drugs: Spectral data-activity relationship
(SDAR) modeling relates nuclear magnetic resonance (NMR) spectra to its activity [54]; structure-activity
relationship (SAR) estimates its activity by sub-structural fragments, physical-chemical properties or
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both [52]; and molecular docking combined with logistic regression (DLR) targets the intimate details
of protein-ligand interactions [55,56]. We also aimed to gain from the consensus of these in silico
models instead of relying on a single method. These models of DDCIs may be useful for regulatory
agencies and public health because they provide a priori estimates of DDCIs before they are
introduced into patients [57].
2. Results and Discussion
2.1. Comparison of in-Vitro-Bioassay and Clinical Data
With the advances in laboratory robotic technologies, increasing attention has been drawn to CYP
HTS data and its use in DDCI model development [52,57–65]. FDA recommends using these data at
the drug-development stage but the final drug labeling is based on clinical trial data [18]. Therefore,
it is of interest to compare the HTS bioassay and clinical inhibition data (since the latter were used for
supervised machine learning in the present work).
The data from two HTS bioassays for CYP3A4 inhibition were available in the PubChem™
database [66], assay identification numbers (AIDs) 884 [67,68] and 1851 [67,68]. AID 1851 was a
combined bioassay with inhibition data for five CYP isoforms, including 3A4; both bioassays covered
large chemical libraries. AID 884 tested 14,155 substances for 13,072 compounds [67,68], and AID
1851 tested 17,143 substances for 16,555 compounds [67,68]. However, many tested compounds were
not on the list of FDA-approved drugs. Presumably, these non-drugs were compounds rejected at the
research and development stages of the drug discovery process. Fewer than 7% of the compounds in
AID 1851 have been identified in PubChem™ as drugs, and no compounds have been tagged as drugs
in AID 884. A query of the bioassays with a 121-compound dataset of the present work revealed that
only 46 and 34 of them were present in the libraries of AIDs 884 and 1851, respectively. Extrapolation
from these numbers (7/100 × 16555 × 46/34/13072) suggests that about 12% of drugs may be present
in AID 884, assuming equal ratios of the overlap between our database and the subsets of drugs in each
of the bioassays. Consequently, FDA-approved drugs were poorly represented in each of the bioassays.
A tested outcome of the AID 1851 bioassay was “whether a compound inhibited pro-luciferin
conversion with any of the five isozymes” [67]. Our reanalysis of the raw kinetic data recorded in
PubChem™ for the aforementioned 34 chemicals did not provide additional information (as compared
with AID 884). Therefore, only the outcomes of AID 884 were used for the comparative analysis
presented in Table 1. In AID 884, the dose-response curve has been constructed using a luciferinlabeled CYP3A4 substrate (6'-phenylpiperazinylyl) [68]. For most chemicals, the dose-response curve
has been measured only once. Multiple curves were only present for chemicals obtained from more
than one vendor. For these chemicals, a mean IC50 and its 95% confidence interval (CI) were
calculated. For single-curve chemicals, a single-point IC50 value (as given by the dose-response curve)
and a mean CI, averaged over all multiple-curve CIs, were applied.
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Table 1. Extrapolation from in vitro bioassay to in vivo pharmacokinetic CYP3A4 inhibition data, and data categorization.
Clinical *

IC50 (95% CI),

Category

AID #884 (µM)

clotrimazole

P

isoniazid
diltiazem

Name

MRDD

BA (%)

R-1 (95% CI)

C-1

0.07 (0.00,0.17)

6.67 ‡ [69]

100

280.33 (115.25,∞)

P

P

9.92 (0.00,26.37)

15 [71]

80 [72,73]

12.03 (5.15,∞)

P

3.98 (0.00,10.88) †

8 [74]

38 [72,73]

8 [75]

†

BA-

R-2 (95%CI)

C-2

R-3 (95% CI)

30–70

196.53 (80.98,∞)

P

280.33 (115.25,∞)

P

P

>70

12.03 (5.15,∞)

P

12.03 (5.15,∞)

2.84 (1.67,∞)

ND

<30

2.45 (1.53,∞)

ND

50 [76]

60.79 (2.07,∞)

P

30–70

84.70 (2.50,∞)

ADME

C-3 Cmax (µM)

R-4 (95%CI)

C-4

0.087 [70]

2.26 (1.51,∞)

ND

P

76.61 [70]

8.73 (3.91,∞)

P

5.85 (2.77,∞)

P

0.356 [70]

1.09 (1.03,∞)

ND

P

120.58 (3.14,∞)

P

7 [77]

56.60 (2.00,∞)

P

1.03 (1.02,∞)

ND

ketoconazole

P

0.13 (0.00,7.03)

glibenclamide

W

5.99 (0.00,12.80)

0.29 [78]

80 [72,73]

1.08 (1.04,∞)

ND

30–70

1.07 (1.03,∞)

ND

1.10 (1.05,∞)

ND

0.2 [77]

methoxsalen

W

10.50 (3.39,17.61)

0.6 [74]

26 [79]

1.07 (1.04,1.21)

W

>70

1.26 (1.16,1.82)

ND

1.26 (1.16,1.82)

ND

0.184 [80]

omeprazole

W

10.00 (3.10,16.9)

†

2 [74]

47 [72,73]

1.27 (1.16,1.88)

W

30–70

1.41 (1.25,2.31)

W

1.58 (1.34,2.87)

W

clemastine

W

5.01 (0.00,13.48)

1.03 (1.01,∞)

ND

30–70

1.05 (1.02,∞)

ND

1.08 (1.03,∞)

ND 0.00233 [82]

dexmedetomidine

W

0.16 (0.00,7.06)

†

lansoprazole

W

nifedipine
pilocarpine

0.134 [81] 37 [72,73]

1.00 (1.00,∞)

ND

‡

0.2 [83]

100

7.30 (1.14,∞)

ND

30–70

5.71 (1.10,∞)

ND

7.30 (1.14,∞)

ND

20.48 (7.63,33.33)

0.5 [74]

81 [72,73]

1.05 (1.03,1.14)

ND

30–70

1.05 (1.03,1.12)

ND

1.07 (1.04,1.18)

ND

1.92 [84]

1.09 (1.06,1.25) ND

W

11.29 (7.70,14.88)

1.71 [85]

50 [72,73]

1.22 (1.17,1.32)

ND

30–70

1.31 (1.23,1.45)

ND

1.44 (1.33,1.64)

W

0.027 [86]

1.00 (1.00,1.00) ND

W

15.85 (8.95,22.75) †

<30

1.05 (1.03,1.08)

ND

1.15 (1.11,1.27)

ND

0.099 [70]

1.01 (1.00,1.01) ND

†

mitoxantrone

W

25.12 (18.22,32.02)

irbesartan

W

15.85 (8.95,22.75) †

losartan

W

19.95 (13.05,26.85)

sildenafil

W

10.00 (3.10,16.9) †

pergolide

1.02 (1.01,1.05) ND

W

12.59 (5.69,19.49)

†

†

0.5 [74]
‡

2 [87]

100

1.18 (1.14,1.25)

ND

<30

1.05 (1.04,1.07)

ND

1.18 (1.14,1.25)

ND

0.36 [70]

1.01 (1.01,1.02) ND

5 [74]

70 [72,73]

1.52 (1.36,1.91)

W

30–70

1.52 (1.36,1.91)

W

1.74 (1.51,2.30)

W

7.98 [88]

1.50 (1.35,1.89)

1.67 [74]

36 [72,73]

1.07 (1.05,1.11)

ND

30–70

1.14 (1.10,1.21)

ND

1.20 (1.15,1.30)

ND

0.596 [89]

1.03 (1.02,1.05) ND

1.67 [74]

38 [72,73]

1.13 (1.08,1.43)

ND

30–70

1.25 (1.15,1.79)

ND

1.35 (1.21,2.14)

ND

0.447 [90]

1.04 (1.03,1.14) ND

0.05 [74]

38 [72,73]

1.00 (1.00,1.01)

ND

<30

1.00 (1.00,1.01)

ND

1.01 (1.01,1.03)

ND

* P = potent inhibitor, W = weak inhibitor; † only a single measurement was available for this chemical, therefore an average error bar for multiple measurements of ±6.9 µM was applied;
MRDD: Maximum recommended daily dose in units of mg/kg/day per oral administration, except when labeled with ‡, which denotes intravenous administration; BA: bioavailability;
BA-ADME: BA calculated using the Human Oral Bioavailability module of the ACD/ADME™ suite, and then the greatest BA in the range was used for calculating R; Cmax: in vivo peak
plasma concentration of inhibitor; R: in vivo AUC fold change; R-1: R extrapolated from the reference MRDD and BA using Equation 6; R-2: R calculated using BA-ADME;
R-3: R calculated assuming BA of 100%; R-4: R extrapolated from Cmax; C-1, -2, -3, -4: Inhibitor categorization based on R-1, -2, -3, -4, respectively.

W
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As shown in Table 1, CIs on the IC50 values were large. A 95% CI exceeded the mean for 71% of
the 17 analyzed drugs. For inhibitors with low IC50 values, which included the potent inhibitors, the
statistics was even poorer: A CI exceeded the mean for 100% of inhibitors with IC50 < 10 µM.
Obviously, the power of analyzed HTS data was hardly sufficient for making inferences, which
highlights the importance of study design in HTS experiments and suggests that a single-point cut-off
on IC50 [58,91] is inappropriate for categorizing HTS data.
Two kinds of changes in activity were observed in the HTS bioassay: Compounds with positive
activity readings, which increased the rate of catalysis of the test substrate, have been categorized as
activators; compounds with negative activity readings have been categorized as inhibitors.
The dose-response curve has been interpreted in PubChem™ for 19 of the 46 drugs of the training set
covered by AID 884, while the kinetics results for 27 drugs have been inconclusive. Of the 19 drugs,
17 were inhibitors and two were activators. These numbers suggest an approximate 10% mismatch
between the clinical and HTS inhibition data (because all drugs recruited in the present study were
categorized as inhibitors based on clinical reports).
In vitro IC50 values have been reported for many compounds in the AID 884 bioassay, but their
relation to in vivo inhibition has not been determined. To map the in vitro data to clinically observable
in vivo bioactivity, the IC50 values were extrapolated to pharmacokinetically relevant quantities.
Following the FDA guidance [18], a ratio, R, of the inhibited area-under-the-curve (AUC) to
uninhibited AUC was used to quantify the in vivo inhibition activity. The extrapolation was carried out
using Equation 6 provided in the Experimental Section. Two approaches were conducted to estimate
the physiological concentration of the inhibitor: One by the maximum recommended daily dose
(MRDD) and bioavailability, and another by the greatest reported clinical plasma peak concentration,
Cmax, which was taken as the maximum hepatic inlet concentration. The results of calculations and
subsequent categorization are presented in Table 1. A threshold of 2 on R was applied for inhibition
strength categorization. Drugs with R > 2 were categorized as potent inhibitors (P = “strong” ∪
“moderate”), while those with 1.25 ≤ R ≤ 2 as weak inhibitors (W). Compounds with R lower than a
threshold of 1.25 were considered to be irrelevant to clinical manifestations of CYP3A4 inhibition.
An agreement between the in vivo and in vitro categorization was poor. More than half of the
in vitro inhibitors could not be categorized. The categorization was not feasible either because the CI
was crossing a threshold on R or because the calculated R was outside the range of in vivo inhibition.
When reported bioavailability values were used for calculating R-1, three of four potent inhibitors and
three of 12 weak inhibitors were identified correctly by in vitro data, giving a 37.5% rate of success.
Calculations of R with bioavailability derived using ACD/ADME™ and with the default
bio-availability of 100% were carried out to test a hypothesis about their utility in the calculations of R.
Bioavailability is a challenging topic for both ab initio modeling and cross-chemical extrapolation [72,92].
Hypothetically, a bioavailability surrogate could be applied to non-drugs in HTS libraries and other
compounds, for which bioavailability has not yet been determined. When using the ACD-calculated
bioavailability or a default bioavailability of 100%, the results of R calculations were similar to
aforementioned R-1. With the ACD-calculated bioavailability, three of four potent inhibitors and two
of 13 weak inhibitors were correctly attributed, giving a 29% success rate; with the default
bioavailability, four of four potent inhibitors and three of 13 weak inhibitors were correctly attributed,
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giving a 41% success rate. Thus, based upon the results of the present study, no evidence suggested
that the default bioavailability of 100% in calculations of R was not appropriate.
Given a well-recognized uncertainty associated with experimentally determined MRDD and
bioavailability values, directly measured plasma Cmax values may be thought of as an appealing
alternative. When Cmax values compiled from the literature and clinical trials (Dr. Minjun Chen
personal communication) were attempted in R-4 calculations, only two of four potent and one of 10
weak inhibitors were assigned correctly. This translates into a 21% success rate, which is almost twice
as poor as the success rate of R-3 calculations with reported MRDD and default bioavailability values.
Within the groups of inhibitors, which were successfully categorized using the in vitro data
(non-NDs in Table 1), no gross miscategorization upon in vitro to in vivo extrapolation was observed,
although an overlap between the clinical dataset and PubChem™ data was small. However, little of the
PubChem™ data were useful for potency categorization because of the low power of underlying IC50
values. Similarly, the IC50 values alone, without extrapolation to in vivo, were of little utility for
inhibitor categorization. Perhaps, deficiencies in the in vitro data can be eliminated in the future with
improved study design, after which the HTS information may become appropriate for modeling
DDCIs. Still, about a 10% mismatch between the HTS measurements and results of clinical trials may
be anticipated. This number is relatively small provided the complexity of the in vivo responses;
the latter is especially important for CYP3A4. CYP3A4 regulation is perhaps the most complex of all
CYP isoforms, because of both peculiarities in the structure/kinetics and system-biological effects.
For instance, both hepatic and enteric forms of CYP3A4 are expressed in large relative amounts, and it
has been shown that these forms are kinetically distinct [93] and may contribute differently to the
pharmacokinetic profile of a xenobiotic. Also, the activity of CYP3A4 is regulated at multiple levels
by inducers, transporters, and other factors [53]. Altogether, a 10% mismatch does not seem
unreasonable but suggests that, even in theory, the performance of HTS data in dissecting DDCIs is
capped below 100% because of causal oversimplification by an in vitro system. To the contrary,
in vivo clinical data are exempt of such a limitation, while their utility depends on a technical
implementation of supervised machine learning; hypothetically, an advanced machine classifier based
on clinical data can be fully successful. However, in vitro systems enable the study of more
combinations of agents than the clinical approaches do. Perhaps, future computational approaches
bearing on both strategies will become most effective.
The PubChem AID 884 bioassay was also used to examine an association between the molecular
weight (MW) and inhibition properties of chemical compounds. A histogram of MWs of compounds
tested for CYP3A4 activity in the AID 884 bioassay was unimodal. It followed a skewed bell-shape
distribution with the mode at 330 ± 30, median at 331 Da, mean at 344 Da, and geometric mean at
316 Da. There were 3,680 compounds active in the test for CYP3A4 inhibition, and 7,418 were
inactive. The histograms of active and inactive compounds were also unimodal and similarly shaped,
but the descriptive statistics were different. The mode, median, mean, and geometric mean of inactive
compounds were 285 ± 20, 294, 311, and 280 Da. Those of active compounds were 350 ± 10, 373,
397, and 378 Da. The 95% parametric CIs on the means were less than 5 Da. These data suggested that
inactive and active compounds dominated different bands on the MW range: The low- and high-MW
bands were populated with inactive and active compounds, respectively.
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The MW histograms of active and inactive compounds were much overlapped and skewed. Because
of that, the optimal point for MW banding was not immediately clear. Ostensibly, the point could be
determined if the underlying theoretical distributions of the active and inactive compounds would have
been known. However, the histograms were imperfectly shaped. An expectation was that MW of a
randomly drawn organic compound follows the lognormal distribution. Descriptive statistics of the
lognormal distribution satisfy the following inequality: {mode = e ( − ^2)} < {median = e } <
{mean = e [ + (^2)/2]}, where  and 2 are the mean = median = mode and variance of the reciprocal
normal distribution on the logarithmic scale. Only the descriptive statistics of active compounds
satisfied the inequality. The MW of active compounds was approximately lognormally distributed with
an estimated mean of 2.578 and standard deviation (SD) of 0.1313 on the log10 scale. For inactive
compounds and dominated by them the full library, the inequality did not hold. It means that although
the general tendency in these histograms was lognormal (as indicated by the median < mean),
the lognormal distribution was inappropriate because the theoretical and observed bell shapes did not
match. Moreover, the histograms of inactive compounds and of the full library could not be
meaningfully fit with neither of normal, lognormal, or Weibull distributions. In these histograms, the
low-MW side of the bell shape seemingly followed the normal distribution, while the high-MW side
resembled a lognormal density. Therefore, unlikely the library of AID 884 compounds was a balanced
random draw. The structure of the distribution suggested an unidentified bias in the HTS dataset that
was caused, perhaps, either by different vendors of the tested substances, or different subsets of the
substances, or maybe several biased draws from the chemical space. Conceivably, the poor-fit
histograms could be described by a superposition of several random processes, but such level of details
was outside the scope of the present study. Therefore, an alternative approach was adopted, in which a
threshold for MW banding was empirically extracted directly from the histograms.
Instead of a ratio of two theoretical distributions, the enrichment with active compounds was
studied using a normalized histogram (Figure 1). Clearly, there was an association between MW and
the frequency of active compounds. The bins were most populous in the low-MW range. There,
a fraction of active compounds increased in a quasi-linear fashion from zero at about 60–172 Da to a
quasi-plateau that began at 450–550 Da (Figure 1). Poor statistics above 1,000 Da prevented confident
characterization of the fraction of active compounds at high MWs. However, there was no evidence
that the fraction was increasing with increasing MW. In the high-MW band the fraction was either
constant at about 0.5, or maybe decreasing at very high MWs. However, in the area of high counts,
the normalized histogram could be almost equally-well fitted with a linear, sigmoid, or bell-shaped
dependence (Figure 1). The shapes of different kind intersected at about 450 Da, which was taken as a
threshold for MW banding.
Among the active compounds, 2,733 had MW lesser and 947 greater than the threshold.
The respective proportions of active/(active + inactive) were 1 = 2733/9278 = 0.2946 (95% CI:
0.2853–0.3039) and 2 = 947/1820 = 0.5203 (95% CI: 0.4974–0.5433). One-tailed Z-test for two
proportions suggested that these proportions were statistically significantly distinct; there was an
almost 100% chance (p < 2.235 × 10−78) that the proportion of active compounds in the low-MW band
was less than the proportion of active compounds in the high-MW band. This was in agreement with
Lipinski's rule of five, which MW condition postulates that MW of drugs with favorable ADMET
properties shall not exceed 500 Da [94]. The ratio of proportions was 2/1 = 1.766 (95% CI: 1.670–1.862),
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i.e., it was about twice more likely to encounter an inhibitor of CYP3A4 among compounds in the
high-MW band compared to the low-MW band.
Figure 1. Normalized histogram of MW of compounds active in AID 884. The number of
active compounds in each bin was normalized by the total number of active and inactive
compounds in that bin. The proportions of active compounds are labeled at the bottom.
The histogram shape was fitted with functions from the bell-shaped and sigmoid families
and with a linear function. In the each family, only the best fit was retained. A fit with a
four-parameter Weibull function (as implemented in the SigmaPlot® software; a = 0.5670,
b = 686.7269, c = 2.0494, x0 = 639.5385) was carried out on the entire domain of MW,
r2 = 0.5837. A fit with the logistic function (y = 0.5047/[1 + (285.1/x)6.266]) was carried out
for MW ≤ 950 Da, r2 = 0.8970. A line (y = 0.001437x − 0.1825) was fitted to the bins in
the range 150–550 Da, r2 = 0.9479. The fitted shapes intersected at about the same point of
450 Da, which was taken as a threshold separating the MW range in a low-MW band that
was depleted with active compounds and a high-MW band that was enriched with
active compounds.

2.2. Docking Classifier of Potent and Weak Inhibitors of CYP3A4
Crystal structures of human CYP3A4 with and without inhibitor correlated with the well-known
structural flexibility of the protein. The flexibility and consequent substrate adaptability of CYP3A4
observed in the structures were consistent with atypical kinetic behavior that has been described for
CYP3A4 [95–97]. MW of CYP3A4 inhibitors studied crystallographically ranged from 226 to 734 Da,
while the volume of active site [98], conjugated to the size of substrate, increased up to 80%. Multiple
substrate binding modes (productive and non-productive) as well as multiple binding sites (at the site
entrance, the catalytic site, and even the secondary binding site) were observed in the crystallographic
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complexes. Based on the structural analysis, four protein data bank (PDB) structures with seven
possible binding pockets were selected for docking studies (refer to the Experimental Section for
details). Four molecular docking programs were applied and, thus, 28 sets of docking scores
were generated.
The docking scores were combined using a logistic regression (LR) procedure. LR variables were
selected either by using the forward-stepwise, backward-stepwise, or a manual selection procedure.
Although the stepwise variable selection procedures are widely used, they are not perfect, and their
drawbacks are well understood [99]. Therefore, an emphasis in the present work was made on manual
selection (a so-called “full” model [99]).
The LR models were trained using 33 potent and 88 weak CYP3A4 inhibitors (see the Experimental
Section for details). Receiver operating characteristic (ROC) curves of the refined interim models are
shown in Figure 2. ROC curves were calculated by varying the cutoff probability point from one on
the left side to zero on the right side of the ROC plot; which cutoff is theoretically most appropriate is
a matter of debate. In practice, the choice of cutoff is often driven by the utility or by cost-effectiveness
considerations. Common choices are 0.5 (SAS® default), or a cutoff point based on prior or posterior
probabilities. The prior or posterior cutoff points are appealing when categories are highly unbalanced,
that is when events in one of the categories are very rare. In this case, a rare-events correction to the
model intercept can be used [100]. In the present work, the categories of the training set were split
approximately 1:3, which suggests that the minority type was unbalanced but not rare. In this case,
increasing the size of the training set and using the default cutoff of 0.5 is a preferred way of handling
the data; appropriately increased size of the training set allows for the adequate representation of
patterns that comprise the minority distribution.
Figure 2. ROC plot of the interim DLR models for potent and weak inhibitors of CYP3A4.
A, B, C, and D denote maximum specificity, maximum correct classification, equal
sensitivity and specificity, and maximum sensitivity points on the ROC curves, respectively.
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As shown in Figure 2, maximum correct classification and equal sensitivity/specificity could not be
achieved with the same cutoff point. A balanced model with equal sensitivity and specificity could be
obtained using a cutoff based on the prior probability of categorization of potent inhibitors (33/121),
which comprised the minority population (Table 2). However, because the training set was
unbalanced, the maximum correct classification could not be achieved with the prior cutoff.
The maximum correct classification was achieved with the default cutoff of 0.5. To maximize the
correct classification, a cutoff of 0.5 was adopted in the present study.
Table 2. Effect of LR probability cutoff on model performance.
Probability
Correct
Sensitivity Specificity
cutoff
classification
maximum specificity
0.60
0.15
1.00
0.77
maximum correct classification
0.50
0.36
0.94
0.79
Forward model
specificity = sensitivity
0.24
0.55
0.57
0.56
maximum sensitivity
0.04
1.00
0.00
0.27
maximum specificity
0.80
0.36
1.00
0.83
maximum correct classification
0.50
0.64
0.94
0.86
Backward model
specificity = sensitivity
0.28
0.79
0.78
0.79
maximum sensitivity
0.08
1.00
0.73
0.47
maximum specificity
0.50
0.42
1.00
0.84
maximum correct classification
Manual model
specificity = sensitivity
0.26
0.68
0.69
0.69
maximum sensitivity
0.10
1.00
0.27
0.47
maximum specificity
0.50
0.72
1.00
0.87
Manual model, maximum correct classification
MW > 450
specificity = sensitivity
0.43
0.78
0.76
0.77
maximum sensitivity
0.07
1.00
0.38
0.64
Model

Cutoff point

ROC AUC is often used as an empirical statistic for model comparison (and its close relationship to
rank tests in non-parametric statistics can be shown). The ROC AUC is interpreted as a measure of
model quality. Clearly, if ROC AUC is 1, the model is perfect, and if it is 0.5 (the diagonal), the
model is worthless. The calculated ROC AUCs were 0.66, 0.89, and 0.80 for the forward-stepwise,
backward-stepwise, and manual selection LR models, respectively. The results suggest that the
backward-stepwise and manual selection models were not excellent (ROC AUC > 0.9), however, but
they were good (ROC AUC > 0.8).
The AUCs were roughly proportional to the number of docking scores recruited in the model: There
were 3, 13, and 7 scores in the forward-stepwise, backward-stepwise, and manual selection LR models,
respectively. As can be seen in Figure 2, the backward-stepwise and manual selection models were
opposite in terms of specificity and sensitivity, i.e., the backward-stepwise model was better at
sensitivity and the manual selection model was better at specificity. Namely, adding more parameters
to the model improved representation of the major category of weak inhibitors but it did not help the
machine classifier to better learn about the minor category of potent inhibitors, perhaps, because of
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under population of the latter. There were 121 compounds in the training set. Applying a 1:20 rule for
candidate predictor variables in a LR model [101], it was perceived that the backward-stepwise model
may be over-trained, while the forward-stepwise may be under-trained. A conservative choice was
made in favor of the manually selected “full” model with a balanced number of parameters.
The manual selection model showed 100% specificity at the cutoff point of maximum correct
classification of the model on the ROC curve (Figure 2), which was achieved using the default
categorizing probability cutoff. Thus, the manual selection model with a categorizing probability
cutoff of 0.5 was adopted as the final model at the LR parameter-optimization stage.
Docking scores included in the final model are presented in Table 3. The table also shows the
contribution and significance of each score. A docking score that was calculated using Surflex™ at the
1W0F-catalytic site gave the highest contribution, while the score that was calculated using FRED™ at
the 2V0M-catalytic site was the next highest contribution. All docking scores were significant for the
final model with p-values of less than 0.05, except for the 1W0F-entrance site score from FRED™,
with a p-value less than 0.1. Six of seven selected scores were pertinent to the catalytic site.
This circumstance suggests that competitive inhibition at the active site is perhaps the major
determinant of the high potency of CYP3A4 inhibition, as given by the chemicals of the training set.
Thus, allosteric sites, which often result in atypical Michaelis-Menten kinetics, must be those that
contribute mostly to weak inhibition of CYP3A4.
Table 3. Summary of the final DLR model.
Analysis of Maximum Likelihood Estimates
Estimated
Standard
Parameter
DF
Coefficient
Error
™
1W0F-catalytic site-by Surflex
1
5.5653
1.5783
2V0M-catalytic site-by FRED™ * 1
−2.2601
0.8146
™
2J0D-catalytic site-by Surflex
1
−1.7176
0.6328
™
2V0M-catalytic site-by Glide
1
1.5078
0.5545
2V0M-full active site-by
1
1.4618
0.5385
FRED™ †
1W0F-catalytic site-by Glide™
1
−1.2597
0.5007
™
1W0F-entrance site-by FRED
1
−1.0350
0.6189
Intercept
1
−1.8088
0.3556

Wald
χ2
12.4342
7.6972
7.3684
7.3927

Pr > χ2

7.3740

0.0066

0.0004
0.0055
0.0066
0.0065

6.3288 0.0119
2.7967 0.0845
25.8789 <0.0001

* The “catalytic site” of 2V0M is referred to the ketoconazole molecule in the active site, which has
its imidazole nitrogen atom within the bonding distance of the heme iron atom; † The “full active
site” of 2V0M also includes a binding site for the second ketoconazole molecule bound to 2V0M in
a non-productive orientation.

The final DLR model constructed using the full training set (the joint model) had a 100%
specificity, 42.4% sensitivity, and a rate-of-correct-classification of 84.3%. A tenfold cross-validation
(CV) was carried out by splitting the training set in a proportion of 1:9 and leaving out the 10% of the
sample. The average model rates-of-correct-classification for ten random splits of the training subsets
(i.e., each subset contained 90% of the total sample) and the CV subsets (10% of the total sample in
each subset) were 83.8% and 79.3%, respectively.
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As shown in the previous section, MW was an important factor affecting inhibition properties of
chemical compounds. Similarly to compounds active in the HTS assay, a histogram of MWs of the
training-set inhibitors also followed the lognormal distribution (p = 0.217, the Shapiro-Wilk test for
normality). The mean was estimated at log10(381), which was indistinguishable from the HTS
geometric mean, and the estimated SD was 0.1885.
When inhibitors of the training set were ranked by MW, the DLR model showed a stepwise
increase in sensitivity at the threshold of 450 Da described in the previous section (Figure 3, Table 2).
Below the threshold, the DLR model recognized only one potent inhibitor (tetracycline), whereas
above the threshold the model recognized almost 75% of potent inhibitors. Nonetheless, it correctly
classified all weak inhibitors, regardless of MW, i.e., there was no false positive error.
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Figure 3. Performance of the DLR model. Potent and weak CYP3A4 inhibitors were
sorted by molecular weight, which is shown in blue; their clinical categorization is shown
in green; calculated probability scores are depicted in red. The dashed line denotes a
chosen probability cut-off for the LR model.
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Adding MW to the pool of docking scores of LR as the 29th independent variable was not helpful:
The coefficient at MW was not statistically significant in the 29- and 7-parameter models (p-value of
0.1375 and 0.2217, respectively). The forward- and backward-stepwise procedures also did not select
MW as a LR variable. MW was not helpful, perhaps, because it was 35–75% correlated with the
docking scores, i.e., it carried redundant information.
To determine if the training set was enriched with potent inhibitors in the high-MW band,
a statistical test was carried out. Among 82 inhibitors in the low-MW band, only 15 were categorized
as potent; among 39 inhibitors in the high-MW band, the number of potent inhibitors was 18.
The respective proportions were 1 = 15/82 = 0.1829 (95% CI: 0.1141–0.2801) and 2 = 18/39 = 0.4615
(95% CI: 0.3157–0.6143). According to the one-tailed Z-test for two proportions, there was a greater
than 99.9% chance that the proportion of potent inhibitors in the low-MW band was less than the
proportion of potent inhibitors in the high-MW band, i.e., that H0: 1 − 2 = 0 could be rejected in
favor of H1: 1 − 2 < 0 (p < 6.50 × 10−4). The power of the test was 93% ( = 0.0676 at  = 0.05).
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It meant that the examined inhibitor data were such that the chance of committing a type II error, when
accepting the null hypothesis, was almost as low as the targeted chance of type I error (i.e., 5%).
Commonly, a study design with the power of 80% is considered acceptable (which implies a four times
lesser penalty for a type II error as compared to a type I error) [102]. Thus, chances of committing both
type I and type II errors were small, which suggests that the size of the training set was sufficient to
confidently conclude that the compounds in the high-MW band were enriched with potent inhibitors of
the CYP3A4 isozyme.
The enrichment of the high-MW band with potent inhibitors was about 50%, i.e., it was similar to
the enrichment with general CYP3A4 inhibitors described in the previous section. In the low-MW
band, however, the fraction of potent inhibitors did not exceed 20%, which was approximately by 30%
less than that described for general CYP3A4 inhibitors in the previous section. Combined, these data
suggested that in the high-MW band CYP3A4 inhibitors were 2–3 times more likely to be potent
compared to inhibitors in the low-MW band. Thus, the effect of MW on potency of CYP3A4
inhibition was more profound than on the category of inhibition itself described in the previous
section. Profusion of inhibitors and potent inhibitors in the high-MW band may be related to a greater
probability of finding a chiral center in large organic compounds. Because CYP3A4 is stereo- and
regio-specific, involvement of enantiomeric decoys unlikely improves but hinders the rate of metabolic
reactions. Preliminary examination of inhibitors of other CYP isozymes (data not shown) suggested
that (1) a similar dependence between MW and inhibition potency can be observed for inhibitors of
other isozymes with adaptive active site, such as 2C9, but unlikely of rigid isozymes, such as 2D6; and
that (2) the MW threshold may be unique for each adaptable isozyme. It is not clear at this point, if the
MW effect is determined by the volume of the active site, or the active-site adaptability, or the number
of binding pockets at the active site (see also Section 2.5). More crystallographic complexes of CYP
isozymes and ligands resolved in the future may help to clarify the topic. Also, if the observed
phenomenon is indeed related to the probability of a chiral center in the ligand, perhaps, the MW effect
will best manifest in isozymes, which spectrum of specificity includes large compounds, i.e., such
CYP isozymes as 3A4 and 2C9.
Now, since the actual proportions of potent inhibitors and their respective CIs were known, they
could be applied to examine the results of machine classification. Suppose that the number of potent
inhibitors in the training set has been forgotten; how many of them will be expected after application
of a machine classifier? The prior suggested an expected range for the number of potent inhibitors.
If the number of machine-classified potent inhibitors would be within 9–23 in the low-MW band and
12–24 in the high-MW band, that would not contradict a statistical expectation at the 95% confidence
level. Similarly, for the whole training set the proportion of potent inhibitors was 0.2727 (95% CI:
0.2013–0.3582). Thus, from 24 to 43 machine-classified potent inhibitors would be expected.
The DLR model correctly classified only 14 potent inhibitors among the 121 compounds of the
training set. That was less than categorized 33 potent inhibitors at 99.9% probability (p < 1.01 × 10−3).
The underestimation stemmed from the low-MW band, in which the correct classification (1/82) was
less than expected (15/82) at more than 99.99% probability (p < 1.15 × 10−4). In the high-MW band,
however, the null hypothesis (that the proportion of correctly classified potent inhibitors, 13/39, is the
same as the proportion of categorized ones, 18/39) could not be rejected (p > 0.123, 87.6%). Thus,
the natural bias in the number of potent inhibitors categorized across the MW range was exaggerated

Molecules 2012, 17

3423

in the classification results of the DLR model. Perhaps, it was caused either by a bias in model training
towards weak inhibitors, which constituted the dominant major category in the low-MW band in a
proportion greater than 4:5, or a statistical fluctuation in the data. Taking into account the results
of DLR model application to the testing set (see Section 2.6), the latter appeared as a quite
likely possibility.
As evident from Figure 3, lowering the probability cutoff point was not helpful, because the domain
of probability scores of weak inhibitors almost exactly overlapped with the domain of potent inhibitors
in the low-MW band. At 450 Da, the probability scores of potent inhibitors displayed a stepwise
increase, which was appropriate for correct classification. The phenomenon could be related either to
an almost 1:1 balance between potent and weak inhibitors in the high-MW band, or to an increase in
the probability of a chiral center discussed above, or, likely, to the number of contacts that ligand
makes at the docking site, i.e., ultimately with the large size and adaptability of the active site pocket
on CYP3A4 (see Sections 2.5 and 3). Another reason could be that the docking study did not cover all
binding sites, especially those with a preference for small molecules such as extra-allosteric sites. It is
also possible that an effector molecule(s) binding may take place when the substrate/inhibitor is small.
For instance, two ketoconazole molecules are bound in one of the crystal structures of CY3A4 used for
docking in the present study [98]. However, at least four molecules of 7-benzyloxyquinoline, which
has MW less than half that of ketoconazole, bind simultaneously to CYP3A4 [14]. Moreover, unlike
other CYP isozymes, the active site pocket of CYP3A4 is enriched with water molecules; the mean
coordination number of water molecules in proximity of the heme is at least two to three times greater
than in other CYP isozymes [103]. However, the docking procedures employed in the present study did
not imply the use of explicit water molecules in docking simulations (although, the mean-field solvent
effects were implicitly accounted for in several of the scoring functions). Water molecules in the active
site may play an important role in protein-ligand binding. On the one hand, shielding the transition
state from water (and thus reducing the activation energy barrier of the transition state) is the main
purpose of enzymatic catalysis (which can be achieved either by elasticity of the active site, or by
presence in the active site of hetero- or homo-effector molecule(s), similar to the 2V0M structure); but
on the other hand, water molecules at high-occupancy hydration sites can mediate the hydrogen-bond
network of the active site and stabilize the protein-ligand complex (along with the conformation of the
protein and the transition state). Also, they contribute to the free energy of binding. Indeed, the process
of ligand binding is also a process of dislodging water from the active site. As water molecules are
released from the active site, the entropy of the protein-ligand complex usually goes down, while the
entropy of the full system (which also includes the solvent) usually goes up (more free water).
However, the arrangement of water molecules in the active site is often different for different ligands.
Docking software used in the present study did not offer modeling of explicit water molecules. Ligand
interactions with water molecules were either neglected or taken into account using a mean-field
approach as implemented in the scoring functions. Recent studies have shown a modest success in
incorporating explicit water molecules in docking simulations [104–106]. Similar methodology applied
to CYP3A4 may improve the accuracy of the DLR model in the future. Also, additional
crystallographic studies on CYP3A4 ligands from the low-MW band may help in understanding the
modalities of small ligand binding and expand the database of docking scores of the model.
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Figure 4 represents the ROC curve and shows performance of the DLR model in the high-MW
band of CYP3A4 inhibitors. The ROC AUC of the model using thus truncated applicability domain
(TD-DLR) was 0.85, i.e., the area outside the ROC curve shrunk by one quarter compared to the
full-domain DLR model (FD-DLR). Similar to FD-DLR, the TD-DLR joint model had 100%
specificity, while sensitivity and the rate-of-correct-classification improved to 72.2% (from 42.4%)
and 87.1% (from 84.3%), respectively (Table 4). The average model rates-of-correct-classification for
the split subsets (90% of the sample) and CV subsets (10% of the sample) of TD-DLR were 84.1% and
70.8%, respectively. That is, the cross-validated model rate-of-correct-classification for TD-DLR was
almost 10% less than for FD-DLR. The latter, perhaps, was related to a smaller volume of training data
in TD-DLR, which training set comprised less than one third of that of FD-DLR.
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Figure 4. (a) ROC curve of the DLR model for the high-MW band (18 potent and 21 weak
inhibitors). A, B, C, and D represent maximum specificity, maximum correct classification,
equal sensitivity and specificity, and maximum sensitivity points, respectively.
(b) Performance of the DLR model in the high-MW band.

Molecules 2012, 17

3425
Table 4. Comparison of SDAR-, SAR- and DLR-modeling * methods.

Modeling
method

Correct
classification
Joint Split CV

Sensitivity
Joint

Split

Specificity
CV

Joint

Split

Type II error
CV

Joint

Split

CV

Type I error
Joint

Split

CV

Number
of descriptors
Joint
Split/CV

SDAR
99.2
95.7 64.9 97.0
90.5 53.3 100
97.7 68.8 3.0
9.5
46.7
0
2.3
31.2
27
12 to 40
SAR
95.0
92.5 66.9 81.8
76.1 27.3 100
97.5 81.8 18.2
23.9 72.7
0
2.5
18.2
5
6.6
FD-DLR 84.3
83.8 79.3 42.4
44.1 35.5 100
98.7 95.7 57.6
55.9 64.5
0
1.3
4.3
7
7
TD-DLR 87.1
84.1 70.8 72.2
71.5 63.3 100
94.6 83.3 27.8
29.5 36.7
0
5.4
16.7
7
7
Consensus 95.0
81.8
100
18.2
0
* The models reported are: “joint”, when all data of the training set was used in the model development (a single value is reported in the
table), and “split”, when only 90% of the data were used in model development, while the remaining 10% were used for CV. The latter two
sets of numbers are the averages over either 10 (DLR) or 100 (SDAR and SAR) random splits of the training set.
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Only five drugs in the high-MW band were misclassified by TD-DLR. However, all of the drugs
belonged to the category of potent inhibitors (as specificity of the model was 100%). The misclassified
drugs were amiodarone, amprenavir, delavirdine, clarithomycin, and erythromycin.
Amiodarone is a vasodilator. It is metabolized in the liver primarily by CYP3A4 and, at low
concentrations, by CYP2C8 (see the Supplemental Material). The rate of catalysis of substrate
luciferin-6'-phenylpiperazinylyl in the in vitro CYP3A4 system has increased in the presence of
amiodarone, as given by PubChem™ bioassay AID 884 (Figure 5); therefore, amiodarone has been
classified in PubChem™ as an activator and not inhibitor of CYP3A4 [68,107]. Although, potency of
CYP3A4 inhibition may vary widely depending on a test substrate [57], we are unaware of examples
in which the sign of reaction rate changes from the inhibition to activation. Of course, hypothetically,
amiodarone can bind to an allosteric site outside the analyzed binding sites within the CYP3A4 active
site pocket in such a way that it acts as an activator for the luciferin-6’-phenylpiperazinylyl substrate
and an inhibitor for some other substrate(s).
Figure 5. Dose-activity data of amiodarone as reported in PubChem™ bioassay
AID 884 [68,107]. A four-parameter Hill equation was fitted to the data.
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Amprenavir and delavirdine are the first-generation antiretroviral drugs for treatment of human
immunodeficiency virus (HIV) infection. Amprenavir is a HIV protease inhibitor, while delavirdine is
a non-nucleoside inhibitor of the HIV reverse transcriptase. Both amprenavir and delavirdine are
mechanism-based inhibitors of CYP3A4. Presumably, delavirdine, binds covalently to the apoprotein
and inactivates it; amprenavir is a substrate but its unknown reactive metabolites also inactivate the
CYP3A4 isozyme [108–110]. Clarithromycin and erythromycin are macrolide ring antibiotics and also
mechanism-based inactivators of CYP3A4. They are first metabolized by CYP3A4 to form reactive
nitrosoalkanes via N-demethylation, which then impair the enzyme [108–110].
DLR is a mechanistic model. As such, it depends on and takes into account the potency of affine
ligand binding of the parent compound. However, to exhibit potent clinical CYP3A4 inhibition effects,
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a mechanism-based inhibitor does not have to be a potent affine binder to CYP3A4, especially if the
isozyme is inhibited by reaction metabolites but not the parent compound. If the parent compound does
not have superior affine-binding properties, a high-fidelity DLR method shall not recognize it as a
potent inhibitor.
In brief, one of the inhibitors (amiodarone) misclassified by the DLR model was, probably, also
miscategorized in the literature, while all other misclassified compounds (amprenavir, clarithromycin,
delavirdine, and erythromycin) were mechanism-based irreversible inactivators, to which the
computational molecular docking approach does not necessarily apply. Taking into account that
machine learning was conducted using clinical, not in vitro, data, it is surprising how reasonably well
the DLR method performed on inhibitors from the high-MW band. It supports a conclusion of the
previous section that only a small part of clinically-characterized CYP3A4 inhibitors disagrees with in
vitro binding-assay data, while most of the clinically observed CYP3A4 inhibition effects originate
from the potent affine binding of interfering agents directly at the active center of CYP3A4. Together
with two other classifiers described in the following sections, the DLR model was incorporated in the
consensus classifier, which was then applied to the EV set (see Section 2.6).
2.3. SDAR Classifier of Potent and Weak Inhibitors of CYP3A4
The average rate-of-correct-classification, sensitivity, and specificity of the SDAR discriminant
analysis (DA) models were 95.7%, 90.5%, and 97.7%, respectively, during the training sessions with a
randomly split dataset (retaining 90% of the data). The complementary 10% of the training set data
were used for CV. During CV the average rate-of-correct-classification, sensitivity, and specificity
were 64.9%, 53.3%, and 68.8%, respectively. Because each time the data selection was repeated
(no information about independent variables was carried over from one run to another), CV for SDAR
DA that is shown in Table 4 essentially was similar to external validation (EV). EV is also often called
the “testing set” if the split of training data is conducted only once. In this sense, the rigor of the SDAR
DA model was examined at a level deeper than conventional SAR/QSAR found in the literature
(because the model never sees the EV until after the training is complete).
Rates of the type I and II errors for the SDAR DA model at the repeated-split training were only
2.3% and 9.5%, respectively. However, they increased to 31.2% and 46.7%, respectively,
at conjugated EV. The low rates of false-positive and false-negative estimates at training and much
higher rates at EV, perhaps, indicate that both the minor and major categories of inhibitors were
under-represented by SDAR descriptors, i.e., that the size of the training set was insufficient to extract
a robust collection of spectral patterns representative of the minority and majority distributions.
Although, the F-score was set to greater than four when selecting the spectral bins for the SDAR DA
model, yet, overtraining of the classifier, perhaps, took place. Expansion of the training set is expected
to stabilize the model.
The final model built using the full training set (referred as the “joint” model in Table 4) showed a
99.2% rate-of-correct-classification, 97.0% sensitivity, and 100% specificity. Only propofol, a potent
inhibitor, was misclassified. Twenty-one of the 157 populated 13C-NMR bins and 6 of the 37 populated
15
N-NMR bins were used during training of the joint SDAR DA model. A number of bins populated
during the tenfold CV ranged from 12 to 40. Of the 27 bins in the joint SDAR DA model, several bins
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had higher coefficients. The 13C bin #176 was a major contributor to the class of potent inhibitors in
the model. It was seen predominantly in the spectra of compounds with cyclic carbon atoms connected
to the oxygen atom of a ketone group. Likewise, the 13C bin #193 was also important and had hits from
two potent inhibitors, doxycycline and tetracycline. The 13C-NMR bin #47 was often present only in
weak inhibitors (19 weak versus one potent inhibitor). The 15N bin #75 was present in five potent
inhibitors, including four conazoles, and one weak inhibitor. The 15N bin #75 was found in inhibitors
with heterocyclic five-member rings that contained more than one nitrogen atom, while the potent
inhibitor ritonavir had a five-member heterocyclic ring with a nitrogen and sulfur atom. The SDAR,
DLR, and SAR (see below) models were merged together by a consensus approach and then applied to
the EV set as described in Section 2.6.
2.4. SAR Classifier of Potent and Weak Inhibitors of CYP3A4
The performance of the SAR classification model of potent and weak inhibitors of CYP3A4 was
estimated by using a tenfold CV. Each cycle of the CV was repeated ten times by randomly splitting
the training set into a training and testing subsets. In total, 100 decision forest (DF) classification
models were generated and tested. At each iteration step the classifier was retrained, i.e., no
information was carried over from one step to another. CV carried out this way is at least as good as
EV repeated ten times. The results showed an average split-training rate-of-correct-classification of
92.5% with a SD of 0.8%, and an average rate-of-correct-classification of 66.9% at testing with a SD
of 3.3%. The results indicated that stable (low SD) classification models of potent and weak inhibitors
of CYP3A4 can be constructed using the given training set. However, the prognostic power of the
models was moderate. Perhaps, it was caused by chemical and structural diversity of compounds in the
training set, for which accurate SAR/Mold2 classification models could be constructed but which could
not be confidently extrapolated to the testing sets. With a larger training set, if coverage of the
chemical space of CYP3A4 inhibitors becomes denser, the accuracy of cross-chemical extrapolation,
perhaps, will increase.
The hypothesis about poor coverage of the chemical space was further evidenced by the analysis of
the molecular descriptors used in the DF classification models. Each DF model had five decision trees;
thus, a molecular descriptor could be used as many as 500 times (100 DF times 5 trees per DF model).
Figure 6 depicts descriptors that were used in the classification models during tenfold CV. The x-axis
indicates the number of trees in which a descriptor was used, while the y-axis shows the number of
descriptors that were used by the same number of trees. A total of 145 molecular descriptors were used
in the models. The average number of descriptors per tree was 6.6. Figure 6 shows that most of the
descriptors were used by a small number of decision trees, indicating chemical and structural diversity
among the different splits of the training set.
There were only three molecular descriptors that were used by more than half of the decision trees
at CV. These top three contributors to the SAR DF models were the Balaban electronegativity
weighted with Pauling-scale index, reciprocal Wiener-type maximum path index, and Balaban-type
polarizability weighted index. These indices reveal that molecular shape (represented by the Wiener
index), electronegativity, and polarizability are the most important quantities relevant to the potency of
CYP3A4 inhibition. Most likely they express molecular properties of inhibitors that bind to CYP3A4,
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such as the activation energy and regioselectivity [111] and interactions of ionizable groups and
permanent dipoles on CYP3A4 [112]. In this case, it would mean that the binding properties are
essential for proper classification of potent and weak inhibitors, and that one of the categories in the
training set, probably potent inhibitors, consists predominantly of CYP3A4 binders.
Figure 6. Distribution of molecular descriptors by DF decision trees built in the process of
CV. Abscissa: the number of decision trees in which the same descriptor was used;
ordinate: the number of descriptors that entered in the same number of decision trees.

During CV, specificity of the SAR DF models was persistently greater than sensitivity. The
specificity and sensitivity were 97.5% and 76.1% at split training, and 81.8% and 27.3% at testing,
respectively (Table 4). The misbalance between specificity and sensitivity was caused perhaps by a
disparity in the training set between positive (33 chemicals) and negative (88 chemicals) outcomes.
Although, more fundamental reasons described above in the docking section could also take place,
especially taking into account that the descriptors picked by SAR DF during training expressed more
the mechanism of binding rather than other possible mechanism of CYP3A4 inhibition.
The final SAR model developed using the full training set showed 81.8% sensitivity and 100%
specificity at the 95% rate-of-correct-classification of potent inhibitor classification (Table 4). Six
potent inhibitors (amiodarone, clotrimazole, diltiazem, haloperidol, propofol, and sertraline) were
misclassified. Only amiodarone had MW greater than 450 Da. Thus, the number of correctly classified
potent inhibitors was 9, 18, and 27 for the low-MW and high-MW range, and the whole training set,
respectively. All numbers were within the limits of statistical expectation described in the docking section.
2.5. Comparison of the DLR, SDAR, and SAR Classifiers
Three very different machine learning classifiers were developed in the present study, and each of
them showed a fairly high rate-of-correct-classification. Table 4 shows a comparison of the DLR,
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SDAR, and SAR model performances during 9:1 split training and CV. The rate-of-correctclassification of the models during tenfold CV was 79.3% and 70.8% for FD- and TD-DLR,
respectively, 64.9% for SDAR, and 66.9% for SAR. Although the methodologies of DLR, SDAR, and
SAR model development were vastly different, the produced models shared a deep fundamental
connection in terms of classification features that were employed by the models to describe the
CYP3A4 inhibitors. The similarities embraced: (1) two major descriptors of the SAR model were
based on electronegativity, while (2) the 13C and 15N-NMR spectra used in SDAR models were
dependent on the electronegativity of the substituent groups connected to the atom; similarly, (3) most
significant independent variables of the DLR model represented scores of the Hammerhead, FRED™,
and Glide™ scoring functions. These scoring functions incorporate electronegativity either in the form
of electrostatic potential, which determines the electronegativity, or its derivatives such as repulsive,
polar, and salvation terms of the Hammerhead scoring function [113]. Because the DLR model
essentially was a mechanistic binding model, the observed descriptor commonality suggested its
association with the potency of CYP3A4 binding. In other words, all methods indicated that the
category of potent inhibitors consisted mostly of potent CYP3A4 binders, while the category of weak
inhibitors consisted either of predominantly weak binders or compounds that set off clinical
manifestations of CYP3A4 inhibition by other mechanisms.
The question arises as to whether a potent clinically observed inhibitor of CYP3A4 must be its
potent binder. An answer may reside with the sensitivity and specificity of the models. During CV the
specificity was consistently higher than the sensitivity as given by all methods, and the final models
came out as 100% specific (Table 4). This suggests that the probability of recognizing a weak inhibitor
as potent was smaller than the probability of recognizing a potent inhibitor as weak. Since a pattern of
potent inhibitors learned by the classifiers seemingly was associated with affine binding to CYP3A4,
other mechanisms related to clinically devised potent inhibition probably were underrepresented in the
training set and, i.e. potent inhibitors of CYP3A4 present in the training set that were not potent affine
binders to CYP3A4 comprised a minor class. They were not appropriately learned by the classifiers
because the size of training set was insufficient for that, and, therefore, they were misclassified by the
models. This could be a likely reason for persistent inferior sensitivity observed for all models.
Similarly, all classification methods summarized in Table 4 showed a relatively high, 37–73% rate
of false-negative estimates during CV. SAR and FD-DLR models had the highest rate of false-negative
estimates. The false-negative rate was high for FD-DLR because the model identified in the training
set only one of 15 potent inhibitors in the low-MW band. For the SDAR model, the true positive rate
was low and the false-negative rate was high, perhaps, because the 1D NMR spectra did not contain
enough chemical structure-specific information to adequately represent diversity of the training set in
the chemical space. Inhibition of CYP3A4 is unlikely to originate from a single carbon or nitrogen
atom as expressed by 1D NMR spectra, but rather from the entire chemical structural entity. The
accuracy of SDAR models may improve as more structural information is added to the spectra, as has
been shown for 3D-QSDAR models [114,115]. Supplementing the carbon and nitrogen chemical shifts
with information about distances between the atoms provides an additional opportunity to more
comprehensively describe the chemical properties of a compound and, thus, improve SDAR modeling.
Extrapolation from the classification results of the final joint models suggests that from 3% to 30%
of non-affine inhibitors of CYP3A4 may be detected as potent in clinical studies. As discussed in the
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docking section, these non-affine inhibitors may be inducers, mechanism-based inhibitors, or perhaps
agents intervening with the active transport and others. The suggested range of numbers is wider but
similar to the 10% mismatch between the HTS measurements and results of clinical trials reported and
discussed in Section 2.1.
Also, there could be compounds that were incorrectly assigned to a wrong category based on
information that was available when the training set was compiled; propofol may be one of them.
Initially, it was attributed to the category of potent CYP3A4 inhibitors based on information external
to the Merck Manual (refer to the Supplemental Material). FD-DLR, SDAR, and SAR classified
propofol as a weak inhibitor of CYP3A4 (while for TD-DLR it was outside the MW domain of the
model). However, later after the work had been completed, propofol was categorized as a weak
inhibitor of CYP3A4 in a new release of the Merck Manual [32].
SAR and TD-DLR both classified amiodarone (MW of 645 Da) as a weak CYP3A4 inhibitor.
As summarized in the docking section, the mechanism of amiodarone interference with catabolism
mediated by the CYP3A4 isozyme is at least more complex than trivial inhibition by affine binding.
However, the final joint SDAR model classified amiodarone as a potent inhibitor. Taking into account
that SDAR showed the lowest of all methods rate-of-correct-classification at CV, SDAR model overtraining may be a reasonable explanation for the discrepancy.
As the SDAR model showed signs of overtraining, and applicability of the DLR model to the
training set was restricted by MW, four additional compounds within the low-MW band shared
false-negative classification from the final joint SAR model. These four compounds were clotrimazole,
diltiazem, haloperidol, and sertraline. It remains to be seen whether these compounds were indeed
misclassified by the SAR and FD-DLR models, or were they miscategorized during compilation of the
training set (perhaps, due to erroneous or incomplete literature information). However, the following
information was subsequently found in the literature:
(1) Clotrimazole is one of the most potent specific reversible inhibitors of CYP3A4 in vitro; it is even
more potent than ketoconazole [116]. However, unlike ketoconazole, its clinical potency is
uncertain [117], and its kinetics is unique in vitro [118], which suggests a uniqueness in the
mechanism of its affinity to CYP3A4, perhaps, involving a distinctive binding modality different
from the “mainstream” affine inhibitors;
(2) Diltiazem is an irreversible (mechanism-based) inactivator of CYP 3A4 [119];
(3) Haloperidol inhibition potency is substrate-specific, ranging from potent (with nifedipine as
substrate) to weak (with testosterone) and less than weak (with felodipine or simvastatin) [120];
(4) Sertraline has been recently asserted as a weak inhibitor of CYP3A4 [121].
It appears that all low-MW drugs misclassified by both DLR and SAR show variability in terms of
CYP3A4 inhibition, which singles out their unique machine learning patterns from the “major” pattern
of potent inhibitors. Perhaps, these minor patterns were on the one hand, distinct enough from the
“mainstream” to deserve separate clusters in the SAR analysis, but on the other hand, statistically
underrepresented in the training set to form well-resolved-mode-of-action based clusters. Therefore,
they were segregated by the SAR model in the group of false-negative estimates.
For compounds in the low-MW band, multiple ligand binding could be thought as a putative
molecular-biologic reason for distinctions between the minor- and major-type learning patterns.
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At multiple ligand binding, some of the molecules may be actual inhibitor(s) of the enzymatic
catalysis, while others may carry a role of homo- or hetero-effectors that change the molecular basis of
the affinity patterns of the actual inhibitors. Apart from several examples of such “molecular
symbiosis” (e.g., ketoconazole molecules in the active site of 2V0M [98]) little is known about the
effectors. It is quite possible that the affinity patterns would be unique for each combination of
multiple ligands. In this case, unlikely even a large database of CYP3A4 inhibitors would be
representative of multiple discretized minority types that may be typical of CYP3A4 inhibitors in the
low-MW band, which would mean the greatest challenge for both experimental (in vitro or clinical)
and computational methods; the smaller is the molecular size (and the larger is the active site),
the more likely misclassification and miscategorization will take place.
2.6. Development of a Consensus Classifier and Its Application to an External Set of Compounds
The developed classifiers were applied to an external testing set of 120 known inhibitors of
CYP3A4 [122], which potency of inhibition has not been documented in the Merck Manual [32].
The DLR, SDAR, and SAR methods identified 25, 34, and 29 compounds, respectively, as potent
inhibitors of CYP3A4. Presuming, both the training and testing sets were drawn from the same general
population, and using proportion priors of the training set, the obtained numbers were within the
expected CI range of 24–43. DLR, SDAR, and SAR identified of the testing set 9, 23, and 13 potent
inhibitors among the 89 low-MW-band compounds, and 16, 11, and 16 potent inhibitors in the high-MW
band (31 compounds), respectively (Table 5). Except for the low-MW-band-FD-DLR result, all
other numbers were within the anticipated ranges of 10–25 and 9–20 for the low- and high-MW
band, respectively.
For the FD-DLR model, the number of potent inhibitors in the low-MW band was slightly outside
the calculated 95% confidence bounds on the mean. However, the direct one-tailed Z-test for two
proportions, in which the calculated potent inhibitors in the low-MW band of the testing set (9/89)
were gauged against the potent inhibitors observed in the low-MW band of the training set (15/82),
suggested that the difference between the two proportion was insignificant at the 95% level
(p > 0.0619), i.e., FD-DLR performed as it is supposed to on the low-MW band of the testing set.
Comparison of proportions of true positive outcomes of the FD-DLR model (i.e., the calculated potent
inhibitors) in the low-MW band using the testing and training sets produced a different result. The null
hypothesis (9/89 = 1/82) was rejected at the 95% level (p < 6.65 × 10−3), and the alternative (9/89 > 1/82)
was accepted. In the high-MW band, the test for proportions did not identify abnormalities in model
performance using both the testing and training set data; the null hypothesis (16/31 = 13/39) was
accepted at the 95% level (p > 0.0615). From these analyses it was concluded that FD-DLR did train
appropriately on the training set, so that it could perform as expected in both the high- and low-MW
bands, as suggested by the results of its application to the testing set. However, in the low-MW band of
the training set it failed to identify a statistically significant number of potent inhibitors for an
unknown reason, perhaps, because of a statistical fluctuation in the data.
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Table 5. External-test compounds classified as potent inhibitors (P) of CYP3A4 by DLR,
SDAR, and SAR in the low- (a) and high-MW (b) bands.
(a)

Compound *
tioconazole
corticosterone
ditiocarb
econazole
oltipraz
piroxicam
quercetin
salbutamol
trimethoprim
troglitazone
almotriptan
bifonazole
carvedilol
dihydralazine
dimethyl sulfoxide
disulfamide
flutamide
ipriflavone
malathion
mequitazine
mizolastine
nilvadipine
nimodipine
oxiconazole
pantoprazole
papaverine
pioglitazone
prednisone
quinelorane
ranitidine
sertindole
sulpiride
theophylline
valdecoxib

FDDLR
P
P
P
P
P

SDAR

SAR

P
P
P
P
P
P
P
P
P
P
P
P
P
P

P
P
P
P
P
P

P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P

(b)

Compound *
dalfopristin
delapril
gallopamil
glipizide
astemizole
calcium folinate
dirithromycin
irinotecan
lopinavir
midecamycin
paclitaxel
raloxifene
reserpine
avasimibe
barnidipine
benidipine
buprenorphine
cerivastatin
efonidipine
flurithromycin
josamycin
lercanidipine
mibefradil
roxithromycin
terfenadine
vindesine

TDDLR
P
P
P
P
P
P
P
P
P
P
P

SDAR

SAR

P
P
P
P

P
P
P
P
P

P
P
P
P
P
P
P

P

P
P
P

P
P
P
P
P
P
P
P
P
P
P
P

* Confidence in compound classification as
potent inhibitor of CYP3A4 is denoted by bold,
regular and italics font for probable, plausible,
and uncertain consensus estimates, respectively.
Probable and plausible estimates were taken as
positive majority rules consensus outcomes for
potent inhibition.

A literature search suggested that of 14 low-MW inhibitors of the training set misclassified by
DLR, four were mechanism-based inhibitors of CYP3A4 (cimetidine [123,124], diltiazem [119],
isoniazid [121], and diclofenac [125]); six were, in fact, either relatively weak inhibitors or inhibitors
of questionable potency (fluconazole [126–129], metronidazole [126,130,131], miconazole [129],
propofol [32], sertraline [132], and voriconazole [133]); and for two of the inhibitors the experimental
data were controversial (clotrimazole [117,118] and haloperidol [120]). The literature on norfloxacin
and doxycycline was scant, which prevented interpretation of classification/categorization of these
compounds. Nevertheless, even changing categorization of the six “relatively weak inhibitors or
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inhibitors of questionable potency” from potent to weak (i.e., using 9/82 and 27/121 in hypothesis
testing for the fraction of potent inhibitors in the low-MW band and on the whole domain,
respectively) did not change any of the reported above results. Thus, no systematic reason in DLR
misclassification of the low-MW compounds of the training set was identified, although the docking
method, in general, is expected to perform better on larger compounds [134]. In this connection, the
validity of classification of dimethyl sulfoxide (DMSO) as a potent inhibitor (Table 5a) was
intriguing. DMSO (MW = 78 Da) was among the smallest compounds in both the training and testing
sets. Surprisingly, DMSO has been reported as a strong inhibitor, which inhibits testosterone
6-hydroxylation by CYP3A4 in a concentration-dependent manner [135]. On the other hand, the
1'-hydroxylation activity of midazolam, which is another standard laboratory substrate for CYP3A4, is
only weakly inhibited by large amounts of DMSO [135]. DMSO was classified as a potent inhibitor
only by DLR. Therefore, it seems that different classifiers partially learned from different aspects of
the minority type populations of the training set.
To increase confidence in classification, the classification methods developed in the present study
were combined using a consensus approach. Several consensus strategies may apply to Boolean
outcomes. They could be either of conjunction, disjunction, majority rules, percent agreement [136],
or even artificial intelligence [60]. Conjunction and disjunction resulted, respectively, in five and 60
inhibitors of the testing set classified as potent. Both numbers were outside the expected CI range.
The null hypotheses about proportions equality to the training set prior were rejected by the one-tailed
Z-test test for two sample proportions at a more than 99.99% probability level.
Synthesis of results was carried out following the strategy of majority rules consensus. Using it,
23 inhibitors of the testing set were classified as potent (Table 5). Similar numbers for the low- and
high-MW bands were 10 and 13, respectively. All the numbers were within the expectancy range.
A hypothesis about identity of the fractions of estimated potent inhibitors in the low- and high-MW
bands was rejected with a 99.99% probability in favor of the alternative that the high-MW range was
enriched with potent inhibitors. This result, obtained by using the estimated potent inhibitors of the
testing set, was similar to one reported above for the actual potent inhibitors of the training set.
This circumstance suggests that the synthetic consensus model accurately learned information that was
available in the training set, so that even a subtle statistical attribute was carefully reproduced.
A percent agreement consensus strategy was applied to assign confidence levels to the classification
results. If potency of inhibitor classification was in full agreement among the DLR, SDAR, and SAR
methods, classification of the inhibitor as potent was regarded as a ‘probable’ outcome. If the
agreement was less than that but more than 50%, the outcome was deemed ‘plausible’. Estimates with
below than 50% agreement between the methods were considered ‘uncertain’.
Dalfopristin, delapril, gallopamil, glipizide, and tioconazole were classified by the consensus model
as probable potent inhibitors, and 18 other inhibitors were classified as plausible potent inhibitors of
CYP3A4. Among the latter, seven chemicals were classified as potent inhibitors by both DLR and
SDAR, five chemicals by DLR and SAR, and six chemicals by SAR and SDAR; i.e., the frequencies
of dual-model conjunction on the testing set of 120 compounds were similar.
A search revealed that about a third of the compounds attributed to the class of potent inhibitors
have been described in the literature as potent inhibitors of CYP3A4. Two of the five probable potent
inhibitors—dalfopristin, a Gram-positive antibiotic, and tioconazole, an antifungal imidazole—have
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been characterized in the literature as strong inhibitors of CYP3A4 [137,138]. Among the 18 plausible
potent inhibitors of CYP3A4, potency information was found for lopinavir, oltipraz, quercetin,
raloxifene, and troglitazone.
Lopinavir is a HIV reverse transcriptase inhibitor, i.e., a drug from a class with many potent
inhibitors of CYP3A4. It has also been reported as a strong inhibitor of CYP3A4 [32,139]. Quercetin
is a plant flavanoid with anti-inflammatory properties. It has been described as a moderate-to-strong
inhibitor of CYP3A4 [140]. Troglitazone belongs to the glitazone family of drugs, which are used to
treat diabetes. Oltipraz and raloxifene are multiple action drugs, although both are often used as
chemo-preventive anti-cancer agents. Troglitazone, oltipraz, and raloxifene form reactive metabolites
(during CYP3A4 metabolism) that have been shown to covalently bind to CYP3A4 [141–143].
As mechanism-based inactivators, they may be considered potent inhibitors of CYP3A4. Interestingly,
neither troglitazone nor oltipraz or raloxifene were classified as a potent inhibitor by DLR. These
drugs corroborate a hypothesis that was formulated in the context of potent inhibitors of the training
set misclassified by DLR (amprenavir, clarithromycin, delavirdine, and erythromycin). This hypothesis
suggests that mechanism-based inactivators together with inhibitors, which affinity-based inhibition
activity is confounded either by effector molecules or at a higher level of biochemical machinery (such
as transcriptional induction), may be outside the domain of potent inhibitors recognized by DLR.
So far, it appears that the docking method associates such inhibitors predominantly with weak potency
of CYP3A4 inhibition.
Mechanism-based inhibitors, perhaps, can be modeled more accurately using inhibitor-structurebased methods, such as SDAR and SAR. Also, the LR part of the DLR model can be supplemented
with inhibitor-structure-based QSAR descriptors, but that would be equivalent to using docking scores
alongside structure-based descriptors in SDAR, SAR or other structure-activity methods. In any case,
improvements in the machine classification of mechanism-based and other minority-type inhibitors
would be possible only if they are sufficiently represented in the training set.
For the other 13 plausible potent inhibitors of CYP3A4 relevant information was not found. Thus,
where experimental data were available, there was a fair correlation between the consensus estimates
and experimental data. The proposed models may be useful in setting priorities for the experimental
testing of drugs and chemicals for interactions with CYP3A4, for screening virtual libraries of
compounds, and for interpreting HTS in vitro data and results of machine learning classifiers that rely
on these data.
3. Experimental Section
3.1. Data Selection
The chemicals used for modeling in the present study were from a dataset of Yap and Chen [33,122].
These authors have compiled information on inhibitors and substrates of CYP isozymes from several
literature sources that are used by clinicians. Inhibition properties of the chemicals have been
cross-checked across several sources to ensure that interlaboratory variations in experimental protocols
do not significantly affect the quality of the information in the dataset [33,122]. There were 241
CYP3A4 inhibitors in the Yap and Chen dataset, which were borrowed for the present study.
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The inhibition potency of these chemicals was attributed based on clinical categorization by the Merck
Manual [32]. The compiled database contained potency information for more than the CYP3A4
isozyme, including 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, and 2E1 (see the Supplemental Material for
details). Among them, 88 chemicals were identified as weak, 16 as moderate, and 17 as strong
inhibitors of CYP3A4. Since the groups were grossly unequal, the strong and medium inhibitors were
combined together to form a set of 33 ‘potent’ inhibitors. This way the training set of the models
became more balanced, with a ratio of potent-to-weak inhibitors of 0.375. Tables 6 and 7 list the
training set of 121 potent and weak inhibitors of CYP3A4 that were used for training of the DLR,
SDAR, and SAR models. The remaining 120 compounds (listed in the Supplemental Material) could
not be categorized by their inhibition potency based on the information provided by the Merck
Manual [34]. These 120 chemicals were used as a set for EV of the developed models. The inhibition
potency of EV compounds was estimated using the three developed classification models and then the
literature was searched to determine the accuracy of these estimates.
Table 6. Training set of potent (P) and weak (W) inhibitors of CYP3A4 in the high-MW band.
Compound
verapamil
delavirdine
pimozide
cisapride
nefazodone
clofazimine
sildenafil
nicardipine
glibenclamide
imatinib
amprenavir
ketoconazole
aprepitant
doxorubicin
atorvastatin
nelfinavir
zafirlukast
ergotamine
dihydroergotamine
etoposide
indinavir
amiodarone
bromocriptine
teniposide
saquinavir
atazanavir
itraconazole

Molecular
weight
455
457
462
466
470
473
475
480
494
494
506
531
534
544
559
568
576
582
584
589
614
645
655
657
671
705
706

Inhibitor
category
P
P
W
W
P
W
W
P
W
P
P
P
P
W
W
P
W
W
W
W
P
P
W
W
P
P
P

Outcome
bioassay-884

Average IC50 (µM)
bioassay-884 *

Inactive

Inactive
Active

10 †

Active

5.99 ± 6.81 (3)

Active

0.13 †

Inactive
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Table 6. Cont.

Compound
ritonavir
clarithromycin
azithromycin
vinorelbine
tacrolimus
docetaxel
vinblastine
troleandomycin
vincristine
sirolimus
quinupristin

Molecular
weight
721
748
749
779
804
808
811
814
825
914
1022

Inhibitor
category
P
P
W
W
W
W
W
P
W
W
W

Outcome
bioassay-884

Average IC50 (µM)
bioassay-884 *

Inconclusive

* Number of repeated measurements (same compound provided by different manufactures) in the
bioassay is shown in brackets and a 95% confidence; † an average standard error on the IC50 with
multiple measurements was 6.90 µM.

Table 7. Training set of potent (P) and weak (W) inhibitors of CYP3A4 in the low-MW band.
Compound
thiamazole
isoniazid
valproic acid
acetaminophen
hydralazine
chlorzoxazone
metronidazole
propofol
selegiline
dexmedetomidine
pilocarpine
methoxsalen
acetazolamide
lomustine
phencyclidine
cimetidine
primaquine
cyclophosphamide
ifosfamide
ticlopidine
mirtazapine
nevirapine
orphenadrine
venlafaxine

Molecular
weight
114
137
144
151
160
170
171
178
187
200
208
216
222
234
243
252
259
261
261
264
265
266
269
277

Inhibitor
category
W
P
W
W
W
W
P
P
W
W
W
W
W
W
W
P
W
W
W
W
W
W
W
W

Outcome
bioassay-884
Inactive
Active
Inactive
Inconclusive
Inconclusive
Inactive
Inactive
Inconclusive
Inactive
Active
Active
Active
Inactive

Inconclusive

Inactive
Inconclusive
Inactive
Inactive

Average IC50 (µM)
bioassay-884 *
9.92 ± 16.45 (2)

0.16 †
15.85 †
10.50 ± 7.11 (3)
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Compound
diazepam
testosterone
anastrozole
diclofenac
cocaine
entacapone
fluconazole
sertraline
fluoxetine
methadone
olanzapine
pergolide
efavirenz
fluvoxamine
norfloxacin
chloramphenicol
quinine
midazolam
clozapine
paroxetine
ciprofloxacin
fentanyl
danazol
dextropropoxyphene
methylprednisolone
clemastine
clotrimazole
omeprazole
nifedipine
voriconazole
oxybutynin
rabeprazole
nitrendipine
prednisolone
drospirenone
lansoprazole
tamoxifen
haloperidol
mefloquine
azelastine
loratadine
felodipine

Molecular
weight
285
288
293
296
303
305
306
306
309
309
312
314
316
318
319
323
324
326
327
329
331
336
337
339
339
344
345
345
346
349
357
359
360
360
367
369
372
376
378
382
383
384

Inhibitor
category
W
W
W
P
W
W
P
P
W
W
W
W
W
W
P
W
W
W
W
W
W
W
W
W
W
W
P
W
W
P
W
W
W
W
W
W
W
P
W
W
W
W

Outcome
bioassay-884

Average IC50 (µM)
bioassay-884 *

Inactive

Inconclusive

Inactive
Active

12.59 †

Inactive
Inactive

Inconclusive
Inactive

Active
Active
Active
Active

5.01 ± 8.47 (3)
0.07 ± 0.10 (3)
10 †
11.29 ± 3.59 (2)

Active
Inconclusive
Inactive

20.48 ± 12.85 (2)

Inactive
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Table 7. Cont.

Compound
nisoldipine
betamethasone
sulconazole
amlodipine
risperidone
fluvastatin
ziprasidone
diltiazem
miconazole
losartan
pravastatin
irbesartan
mifepristone
doxycycline
mitoxantrone
tetracycline

Molecular
weight
388
392
398
409
410
411
413
415
416
423
424
429
430
444
444
446

Inhibitor
category
W
W
W
W
W
W
W
P
P
W
W
W
W
P
W
P

Outcome
bioassay-884

Average IC50 (µM)
bioassay-884 *

Inactive

Active

3.98 †

Active

19.95 †

Active

15.85 †

Active

25.12 †

*,† The same as in Table 6.

3.2. Analysis of CYP3A4 Inhibition using HTS Bioassays
HTS bioassay outcomes were obtained from PubChem™ [28]. A query for CYP3A4 inhibition was
performed, and 1,333 hits were found. However with few exceptions, all datasets contained less than a
hundred chemicals. The exceptions were two HTS bioassays, AID 884 and 1851, both conducted by
the National Institutes of Health Chemical Genomics Center. AID 1851 was a combined bioassay with
inhibition data for five CYP isoforms, including CYP3A4 [67]. An IC50 has been reported for the
chemical tested in the bioassay but the strength of their inhibition has not been categorized. AID 884
was a dedicated CYP3A4 inhibition assay, in which the inhibitors were categorized as active, inactive,
and inconclusive [68].
Extrapolation from the in vitro data to in vivo inhibition activity was carried out following the FDA
guidance [18]. The guidance is based on Michaelis-Menten kinetics for competitive inhibition. It can
be shown that, under conditions of competitive inhibition, the apparent Michaelis constant of the
substrate-to-product enzymatic conversion reaction, Km,i, is scaled from its uninhibited value Km by a
factor of

R

Km,i
I 
 1 ,
Km
Ki

(1)

where [I] is the concentration of inhibitor and Ki is the dissociation constant of the enzyme-inhibitor
complex called the inhibition constant. At low concentrations of substrate, the Michaelis-Menten
equation becomes

V  Vmax

S 
,
Km

(2)
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where V and Vmax are the reaction velocity and maximum reaction velocity, respectively, and [S] is the
concentration of substrate. When the substrate is bioconverted, i.e., cleared, the reaction velocity can
be expressed in terms of apparent intrinsic clearance, CL, as V = [S] × CL, and, therefore,

CL 

Vmax
.
Km

(3)

Since the dose or exposure expressed in terms of pharmacokinetic AUC is inversely proportional to
the clearance, and the maximum velocity of reaction does not change under conditions of competitive
inhibition,

R

K m ,i
Km



CL AUCi
.

CLi AUC

(4)

A concentration of inhibitor that decreases the rate of reaction at a specified concentration of
substrate by half, IC50, is related to the inhibition constant by the equation of Cheng and Prusoff [144]:
IC50 

Ki
.
S
1  K 

(5)

m

At low concentrations of substrate, Ki ≈ IC50. Therefore,

R

AUCi
I  .
 1
AUC
IC50

(6)

The equation implies competitive inhibition and that the substrate is metabolized by only one
enzyme isoform in one metabolic pathway. The equation also holds for noncompetitive inhibition.
Equation 6 becomes more complicated in case of uncompetitive inhibition or if several
enzymes/pathways are involved.
Two approaches were exercised to estimate the concentration of inhibitor [I]: one by the MRDD
and per oral bioavailability, and the other by the maximum concentration of inhibitor in serum (Cmax)
that has been reported in clinical trials. The latter approximates the maximum hepatic inlet
concentration. For the analysis presented in Table 1, a cutoff of 2 on R was applied for inhibition
strength categorization. Drugs with R greater than 2 were categorized as P (potent, i.e., a strong or
moderate inhibitor), while those with R between 1.25 and 2 as W (weak inhibitor). This was in
compliance with FDA guidance, in which inhibitors that increase the substrate AUC by fivefold or
higher are labeled as ‘strong’, inhibitors that increase it between twofold and fivefold are labeled as
‘moderate’, and those that increase it between 1.25-fold and twofold are labeled as ‘weak’ [18].
3.3. Selection of CYP3A4 Crystal Structures for Docking
Six crystal structures of human CYP3A4 isozyme were available from PDB [145] (codes: 1TQN,
2J0D, 1W0E, 1W0F, 1W0G, and 2V0M, 2.80 [98,146,147]). Their resolution and a free R-factor
(i.e., a statistics collected in crystallographic refinement using a EV set) ranged from 2.05 Å to 2.80 Å
and from 0.271 to 0.318, respectively. Only the best quality structures among the structurally similar
PDB codes were selected for docking studies. They included four structures, one without inhibitor
(1TQN) and three with inhibitors (1W0F, 2J0D, and 2V0M) [98,146,147]. The heme group with a
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catalytic iron ion was well refined in all structures, as given by relatively low B-factors on the heme
atoms. The substrate binding site was located next to the heme. A profound conformational change was
observed in the structures with bound substrate/inhibitor. The conformational rearrangement involved
opening of two loops flanking the active site to a different extent to accommodate the inhibitors of
different sizes (Figure 7). Five residues in the loop connecting the F and F′ helices were absent in the
2J0D structure due to poor quality of the electron density in this region. Perhaps, the F-F′ loop in 2J0D
was too flexible for adequate description by a single static set of mean coordinates, unlike the rest of
the structure. CYP3A4 can metabolize various classes of substrates, and it does not follow the
Michaelis-Menten type kinetics. Based on kinetic studies, Kenworthy’s group has proposed that three
sub-pockets may exist within the active site of CYP3A4 [119]. Another hypothesis is that multiple
kinetically distinguishable conformations of CYP3A4 are present, with or without substrate, effector,
or inhibitor [14,146,148,149]. External factors such as interactions with CYP-reductase, cytochrome b5
and its reductase, and the presence of membrane phospholipids may stabilize particular conformations
of CYP3A4 and affect its activity toward certain chemicals [146,150]. As shown in Figures 7 and 8,
the four selected structures represented different binding sites as well as different sizes/conformations
of the CYP3A4 active site pocket, including expanded ones. 1TQN is a ligand-free structure with the
smallest empty pocket [147]. A hydrophobic phenylalanine (Phe) cluster is located in proximity of the
catalytic heme. A peripheral auxiliary binding site can be observed in the CYP3A4-progesterone
complex (1W0F). It is located at the gate to protein surface, i.e., it is distal to the heme and Phe cluster.
It may be involved in the initial recognition of substrates or allosteric effectors [146]. The catalytic site
of 1W0F was almost identical to 1TQN, 1W0G, and 1W0E. However, unlike these four structures,
2J0D and 2V0M revealed dramatic conformational changes upon ligand binding (Figure 7). In these
two structures, the volume of active site was significantly increased (by more than 80% in 2J0D [98]).
These two complexes represented two distinct expanded conformations of CYP3A4 because
erythromycin A and ketoconazole induced different types of coordinate shifts in the isozyme.
In 2J0D, one erythromycin molecule is bound in a non-productive mode with the reactive
D-desosamine group located 17 Å away from the heme iron atom [98]. However, in 2V0M a
ketoconazole molecule resides within the bonding distance between its imidazole nitrogen atom and
the iron atom of heme (referred to as first binding site in the docking procedure). Moreover, the active
site of 2V0M enfolds the second ketoconazole molecule. It is stacked on the first one in an anti-parallel
orientation [98] (referred as second binding site in the docking procedure), as shown in Figure 7. These
structural features were consistent with wide substrate adaptability that is well-known for CYP3A4,
suggesting that this isozyme possesses an extremely flexible and multifunctional active site pocket.
Multiple binding modes and multiple binding sites on CYP3A4 were seen in the present study, which
is consistent with atypical kinetics data for this isozyme [95–97].
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Figure 7. An active site view of superimposed crystal structures of the human CYP3A4
isozyme. 1TQN (no bound molecule) is shown in orange, 1W0F (with bound progesterone)
in magenta, 2J0D (with bound erythromycin A) in green, and 2V0M (with bound
ketoconazole) in cyan. The catalytic iron atom of the heme moiety is shown as a red van
der Waals sphere. The active site volume is confined by the heme on the left and a flexible
F–F′ loop that flanks the active site on the right. Nitrogenated sites-of-metabolism (SOM)
on the ligands are shown in blue. As evidenced by the disposition of ketoconazole SOM in
respect to the heme, ketoconazole is regioselectively bound at the substrate site next to the
catalytic heme group (on the left), while erythromycin, although at the same site, is bound
in a non-productive (inhibiting) orientation. Progesterone is bound at an allosteric binding
pocket at the entrance of the active site of 1W0F (on the right). The active site of 1W0F is
ligand-free and, thus, similar to ligand-free 1TQN as evidenced by overlapping positions of
the flanking loop (left end of the white arrow). Upon substrate binding, the loop expands
first to accommodate two ketoconazole molecules (2V0M, middle of the white arrow) and
then further, to accommodate an even larger erythromycin A (2J0D, right end of the white
arrow). Thus, the white arrow points at the most contracted and the most expanded
conformations of the flanking F–F′ loop. The active site expands from the left to the right
of the arrow to fit the size of substrate, and when the loop is at the right-most position
(2J0D), volume of the active site is increased by more than 80% [98]. The green dashed
trace denotes five disordered residues of the flanking loop, for which the coordinates have
not been resolved in the 2J0D structure because of poor electron density in that region.
Note the second ketoconazole molecule at the bottom (thin white); it is bound to the same
crystal structure 2V0M but in a non-productive pose at an auxiliary pocket within the
active site of CYP3A4, which expands to accommodate both molecules.

F'
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Figure 8. Superimposed docking sites of the human CYP3A4 isozyme. The trace of 1W0F
structure (with bound progesterone) is denoted by the magenta ribbon. Each box represents
a docking area of interest. The progesterone allosteric binding pocket area at the entrance
of the 1W0F active site is represented by the magenta box; the catalytic site area of 2J0D
(where erythromycin A is bound) is represented by the green box; the catalytic site area of
2V0M (where one of the ketoconazole molecules is bound) is represented by the cyan box;
the auxiliary pocket area in the active site of 2V0M (that holds the second ketoconazole
molecule) is represented by the white box; the area of the full active site in 2V0M is
represented by the red box. The areas occupied by the catalytic site in 2V0M, 1W0F, and
1TQN structures are almost identical upon superposition. Therefore, the latter two are not
shown for clarity.

3.4. DLR Methods
Docking studies were carried out using four programs: eHiTS®/CheVi® (SimBioSys, Inc.; Toronto,
Canada); FRED™ as a part of the OpenEye software suite (OpenEye Scientific Software, Inc.; Santa
Fe, NM, USA); Surflex™ as implemented in Sybyl® (Tripos, Inc.; St. Louis, MO, USA); and Glide™ as
a part of the software suite from Schrödinger, Inc. (Portland, OR, USA).
No protein heavy atom minimization (or other resampling) was carried out in the present study.
Coordinates of heavy atoms in modern crystallographic structures are already a product of geometry
optimization consistent with experimental electron density. The electron density in turn is a time- and
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volume-averaged quantity. In the present work computational molecular docking was carried out using
a PDB-deposited structure (rather than a thermodynamic ensemble of microscopic structural states in
aqueous environment), thus, employing an unperturbed average structure was appropriate because it
naturally represented the best averaging over a real physical-chemical thermodynamic ensemble
observed in crystallographic experiments. The grand canonical ensemble was imitated by combining
scores from four different crystallographic structures.
High chemical diversity of CYP3A4 substrates added complexity to docking modeling. Thus,
for each of the four docking programs, seven docking sites were considered: 1TQN-catalytic site,
1W0F-catalytic site, 1W0F-entrance site, 2J0D-catalytic site, 2V0M-catalytic site, 2V0M-secondary
binding site and 2V0M-full catalytic site. To avoid artifacts, the missing residues on the flanking loop
of the 2J0D structure were left unreconstructed because molecular docking in this structure was
focused at the catalytic site next to the heme and away from the unresolved part of the loop.
3.4.1. eHiTS®
eHiTS® implements a docking algorithm that involves a flexible ligand/rigid receptor methodology.
It uses an exhaustive flexible-docking method starting with dividing the 3D structure of the ligand into
rigid fragments and flexible chains. The rigid fragments are then docked independently into the
receptor site and their poses, with flexible chains, are reconstructed by a graph-mating algorithm.
The final poses are locally minimized and the score of each pose is reported.
3D coordinates for each the 121 training chemicals were generated using the Corina™ software
(Molecular Networks, GmbH; Erlangen, Germany) as implemented by the Computer-Aided Drug
Design Group at the National Cancer Institute [151]. Hydrogen atoms were added to each ligand.
eHiTS® automatically took into account all possible protonation states of each ligand–receptor pair,
so no preliminary preparation of specific protonation states of ionizable ligands was necessary.
Docking was performed by eHiTS® Version 6.2 at the maximum accuracy setting. The docking area
was set to 7 Å from the residues forming the active site. All other settings were kept at defaults.
The score.sh script supplied with eHiTS® Version 6.2 was used to calculate and rank the scores of
docked compounds.
3.4.2. FRED™
FRED™ relies on another exhaustive configurational searching algorithm. Unlike eHiTS®, instead
of splitting ligand into fragments, it first generates all appropriate conformations of the ligand. Then it
examines each pose within the protein active site, filtering them by shape complementarity and
pharmacophoric features before selecting the final pose based upon a consensus of scoring functions.
Before actual docking, pKas, protonation states and AM1-BCC partial charges were assigned to all
atoms of the ligand using the Pkatyper™ and Molcharge™ programs from the QuACPAC™ 1.3.1
package. Then the Tautomers™ program from the same package was applied to enumerate possible
tautomers. Tautomers at all possible levels were generated. The enantiomers and 3D coordinates of
each compound were constructed by Omega™ 2.3.2 package. The default Omega™ settings were kept
except for the following: the maximum number of output conformers (“maxconfs” option) was set to
500 and a root-mean-square Cartesian distance (“rms” option), below which two conformations were
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deemed duplicates, was set to 0.8 Å. Both QuACPAC™ and Omega™, along with FRED™, are parts of
the OpenEye software suite. Receptor proteins were prepared using FRED-receptor™ 2.2.5. The shape
of active site was described by two contours of the shape potential, an inner and outer one. The inner
contour was set to 80–120 Å3, while the outer to 1,200–1,500 Å3. Docking was performed using
FRED™ 2.2.3 in two steps, the shape fitting and optimization. During the shape-fitting step, a ligand
was put into a 0.5-Å-resolution grid box around atoms of the active site using a smooth Gaussian
potential. Several scoring functions were provided with FRED™, including Shapegauss, PLP, Chemgauss2,
Chemgauss3, and CGO functions [152,153]. To rank the poses, a consensus scoring was used.
3.4.4. Surflex™
3D structures of inhibitors from the training and test sets were generated using the Unity translator,
which was a part of the local Sybyl® 8.1 package. Subsequent docking was performed using the
Surflex-Dock™ module. Surflex-Dock™ combines a scoring function from the Hammerhead docking
system with a search engine that relies on a surface-based molecular similarity method [153–155].
Similar to eHiTS®, the ligand is fragmented into pieces before docking.
Each crystal structure was first preprocessed. Hydrogen atoms were added and minimized using the
Structure Preparation Tool. The active site was identified and a conservative residue-based protomol
was built with “proto_thresh” and “proto_bloat” set at 0.5 and 0.0, respectively. Then the protomol
was visualized, its stray fragments were trimmed, and then the protomol was used to match the
docking ligand fragments. Starting with the head fragment, other fragments were aligned one by one.
A maximum limit of 50 conformations per fragment was set in each stage of the incremental
construction process. Default settings were kept for all other parameters. Finally, the combined poses
were refined and the 30 top-scored poses were reported.
3.4.5. Glide™
The Glide™ algorithm aims for a complete systematic search of the conformational, orientational,
and positional space of the docked ligand [156,157]. In this search, ligand conformations were first
enumerated using LigPrep™, including the ionization states (a tool, Epik™, was used with target pH set
at 7.0 ± 3.0), tautomers (as many as 16 tautomers per ligand), and enantiomers that specified which
chiralities were retained; chiralities at other chiral centers were varied. The lowest energy ring
conformation was produced for each inhibitor with a ring component. All enumerated structures were
then filtered to remove structures that could cause subsequent processing failures either at the stage of
energy minimization or at other stages, for instance, because of improper ionization state. After that,
the geometries of retained structures were optimized.
The protein structure was pre-processed using the Protein Preparation Wizard. Bond order
topologies were generated. Hydrogen atom positions were calculated and optimized for hydrogen
bonding. For docking, Glide™ uses two boxes to define the active site: an outer grid-enclosing box and
an inner ligand-diameter-midpoint box. The center of the outer box was determined by the centroid of
the bound ligand as given by the original PDB file, or centroid of selected binding site residues if the
ligand in the binding site was not present. Then the box was expanded to cover the whole active site.
A 12-Å inner grid box was set to confine the ligand center. All other parameters were kept at their
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defaults. Docking precision was set at the extra precision (XP) level. During docking, the receptor was
represented by the rigid grid, while the ligand was flexible. In the process of docking, an initial rough
positioning and scoring was implemented to eliminate most unfavorable poses, which was followed by
the grid energy optimization. Schrödinger GlideScore™ XP, a proprietary, empirical, multi-ligand
scoring function, was applied. The geometry of poses of top-scored candidates was further optimized
by full post-docking minimization, which relaxes strained ligand geometries and eliminates poses with
unfavorable energy, i.e., suboptimal bond length and angles, with eclipsing interactions, too many
intraligand close contacts, and so on. The all-atom OPLS-2001 force field [158] was used. After that
the poses were rescored using the GlideScore™ with a scaled OPLS term for non-bonded interactions.
As many as 15 poses for each ligand were kept for reporting.
3.4.6. Logistic Regression Modeling of Docking Scores and Statistical Analysis
LR models were built to combine the docking scores from 28 docking runs (four programs by seven
binding sites in four CYP3A4 crystal structures). The docking scores were converted to standard
scores (or Z-scores) before LR model construction. The SAS® version 9.0.2 software was used
(SAS Institute, Inc.; Cary, NC, USA). An automated stepwise regression procedure (forward and
backward methods) [159,160] and manual selection of the best predictive variables were carried out.
The selection of variables for the model was based on the Wald 2 test. Variables, whose coefficients
were statistically significantly different from zero with p-value of 0.05 or less, were recruited in the
model. Note, when formation of the model is completed and the significance of coefficients is
recalculated, the new and old p-values may not be the same. Models were evaluated based on their
performance, number of parameters, and the ROC curves. Only models with ROC AUC greater than
0.8 were given further consideration. Therefore, in the manual selection procedure first variables,
whose coefficients remained significant at  = 0.05 in the full model, were selected. Then, the manual
model was supplemented with the least number (one) of additional variables with less-significant
coefficients (p-value lesser than 0.1), which made model’s ROC AUC greater than 0.8. Chosen this
way, the final manual LR model with the least number of parameters (seven) was adopted as a
classifier of potent/weak CYP3A4 inhibitors, in which a LR probability cutoff of 0.5 was used to
perform classification.
CIs for population proportions were calculated using Wilson’s method without continuity
correction [161]. The identity of population proportions was tested using two-sample proportions
procedures, as implemented in JMP® 9.0.1 (SAS Institute, Inc.; Cary, NC, USA). SigmaPlot 10.0
(Systat Software Inc.; Chicago, IL, USA) was used for curve fitting.
3.5. SDAR Methods
SDAR modeling relates NMR spectra of a chemical to its activity [54], and SAR modeling relates
substructural fragments, physical-chemical parameters of a chemical or both to its biological or
toxicological activity or physical properties.
A *.mol file of each of the chemicals shown in Tables 6 and 7 was processed using ACD/CNMR
Predictor™ of the ACD/Labs™ version 12.0 software suite (Advanced Chemistry Development, Inc.;
Toronto, Canada), its 13C-NMR spectrum calculated, and the spectrum exported in a text file. The 15N
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spectra for each compound were calculated using the ACD/NNMR Predictor™ software module from
the same vendor. The 13C spectrum of each compound was binned by software written at NCTR using
bin widths of 1 ppm (C1), while the 15N spectra were binned using the same software for bin widths of
5 ppm (N5). All discriminant analyses were performed using a Statistica® version 8.0 software package
(StatSoft, Inc.; Tulsa, OK, USA). DA training models of potent and weak inhibitors to CYP3A4 were
built using C1 and N5 bins populated with at least three hits and using forward regression F > 4.0 to
enter a bin to the DA model. No bins with only three hits were selected and only one bin had four hits.
Previously, the forward regression on lower F was used to develop models for classification of
inhibitors and non-inhibitors of CYP3A4 [122]. A more conservative SDAR DA model with smaller
bin sizes was chosen for classifying potent and weak inhibitors in the present study, because there were
expected to be fewer spectral and structural differences between potent and weak inhibitors than
between inhibitor and non-inhibitors of CYP3A4. The SDAR classification DA models were
constructed with prior probabilities of classifications (potent inhibitors/ weak inhibitors) set as equal
for all DA SDAR models [162].
3.6. SAR Methods
Molecular descriptors are used to extract structural information in a form of numeric representation
that is suitable for model development. Thus, the descriptors serve as the bridge between the molecular
structure and biological activity of the chemical. Previously we developed Mold2, a software package
for calculating 777 molecular descriptors [163]. Mold2 was used to calculate molecular descriptors for
the training and test compounds used in the present work. Thereafter, Shannon entropy, also known as
information entropy, was used to filter descriptors with low information content. This resulted in 327
of the descriptors remaining for modeling potent and weak inhibitors of CYP3A4. The resulting
informative descriptors, with the assignment of compounds as potent or weak inhibitors of CYP3A4,
were used to construct classification models.
DF [163–165], a classification method developed in our laboratories, is a novel pattern recognition
method that combines the results of multiple distinct but comparable decision tree models to reach a
consensus estimation. In training a DF model, five decision trees were generated by using Gini's
diversity index for splitting the nodes in the trees. This process was used to construct classification
models for estimating potent and weak inhibitors of CYP3A4 isozymes.
3.7. Cross-validation of SAR, SDAR, and DLR Models
Tenfold CV was used to measure the classification performance of SAR, SDAR, and docking
models. At each iteration, the training data set was first randomly divided into ten equal portions, and
then each was successively excluded from the training set and calculated using a model developed
from the remaining nine portions. The rate-of-correct-classification at CV was taken as an average
over ten iterations. Each random division of the data set into ten portions leads to ten specific pairs of
training and test sets that could be biased in terms of the rate-of-correct-classification. The training
and cross-validation models were evaluated in terms of their sensitivity, specificity, and the
rate-of-correct-classification.
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4. Conclusions
The CYP3A4 isozyme biotransforms a plethora of drugs and environmental xenobiotics. As such,
it is instrumental in controlling the physiological levels of drugs and their metabolites. The mechanism
for ligation to CYP3A4 can be either mediated by covalent bonding of the agent or its reactive
metabolites, or by reversible binding of the inhibitor [166]. The binding of an inhibitor can occur at
multiple sites on the isozyme, the structure of which appears to be very flexible [14,95,96,119,167].
In addition, modulation of the apparent catalytic activity in vivo may also occur at higher levels of
biochemical organization [17,18]. Therefore, modeling potent and weak inhibitors of CYP3A4 can be
challenging. Because of these potential complications, multiple independent modeling methods to
classify potent and weak inhibitors of CYP3A4 were applied. Each of the models performed
adequately, but not perfectly, as each method viewed the problem differently. The SDAR and SAR
methods were primarily based on structure and physical descriptors that can be related to the chemical
itself, while the DLR relied on scores of interaction energies between the chemical inhibitor and the
enzyme. In this regard, the SDAR and SAR approaches are more general. Conceivably they can learn
from different minority patterns embedded in the training set, provided that the training set is
representative of each of them. In the present study, however, the size of the training set prevented
realization of the full potential of SDAR and SAR methods, limiting their performance to largest
uniform mode-of-action groups of inhibitors, which were either direct reversible binders or
mechanism-based inactivators of the isozyme. In this situation, the DLR results appeared very
favorable. Although, the DLR method hardly identified any mechanism-based inhibitor, it performed
extremely well on reversible binders showing the highest overall results in CV. Taking into account
the complexity of CYP3A4 and diversity of regulatory mechanisms, such an outcome was surprising.
It confirmed a proposition that selective strong binders to the isozyme carry the greatest clinical
importance. Also, it suggested that the large size of a reversible inhibitor is an important determinant
of its high potency of inhibition. In this regard, comparison of clinical and HTS in vitro data was
insightful. It indicated that in clinical trials, perhaps only a small fraction of modern drugs inhibits
CYP3A4 activity by means other than direct interference with MFO. As the cost of in vitro screening
decreases and study design improves, the HTS assessment of DDCIs may become a valuable adjunct
in public health practice.
To increase confidence in machine classification, the DLR, SDAR, and SAR methods were
combined by consensus modeling. When the consensus model was applied to an external testing set of
120 inhibitors, the consensus estimates were within the limits of statistical uncertainty (extrapolated
from the testing set). Using a majority-rules consensus, five compounds of the testing set were
classified as probable potent inhibitors (by all three methods). Subsequently, two of them were
identified in the literature as known potent inhibitors. Eighteen additional compounds were classified
as plausible potent inhibitors (by two of the three methods), and a literature search confirmed
approximately a third of them. Likewise, when all of the models agreed that the chemical was a weak
inhibitor of CYP3A4, no information was found in the literature stating that these chemicals are potent
inhibitors. Many of these inhibitors may be partially responsible for changes in pharmacokinetics,
pharmacodynamics, and possibly adverse reactions in people taking multiple drugs (polypharmacy),
nutritional supplements, or exposed to hazardous chemicals. Therefore, these people should be either
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monitored by physicians or, at minimum, the chemical mixture, to which they are exposed to, be
computationally evaluated for possible DDCIs before the polychemical therapy or exposure is started.
The consensus methodology described in the present report provides means to do that. In the
consensus, computational molecular docking supplied information that was complementary to
traditional SAR and SDAR. Combined, these modeling methods provided a promising assessment of
CYP3A4-mediated DDCIs, and suggested that a consonant use of multiple models may facilitate
investigation of other complex systems in pharmaceutical and environmental toxicology.
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